(e) CERTAIN RULES TO APPLY.—For purposes of this section, rules similar to the rules of sections 51(i)(1) and 280G(a) of the Internal Revenue Code of 1986 shall apply.

(f) CERTAIN GOVERNMENTAL EMPLOYERS.—This credit shall not apply to the Government of the United States, the government of any State or political subdivision thereof, or any agency or instrumentality of any of the foregoing.

(g) ELECTION TO HAVE SECTION NOT APPLY.—This section shall not apply with respect to any eligible local newspaper publisher for any calendar quarter if such person elects (at such time and in such manner as the Secretary may prescribe) not to have this section apply.

(h) SPECIAL RULES.—

(1) EMPLOYEE NOT TAKEN INTO ACCOUNT MORE THAN ONCE.—An employee shall not be included for purposes of this section for any period with respect to any employer if such employer is allowed a credit under section 51 of the Internal Revenue Code of 1986 with respect to such employee for such period.

(2) DENIAL OF DOUBLE BENEFIT.—Any wages taken into account in determining the credit allowed under this section shall not be taken into account for purposes of determining the credits allowed under section 41, 45A, 45P, 45S, 51, 1396, 3431, 3432, 3134, and 6432 of such Code.

(3) THIRD-PARTY PAYORS.—Any credit allowed under this section shall be treated as a credit described in section 3641(d)(2) of such Code.

(i) TREATMENT OF DEPOSITS.—The Secretary shall waive any penalty under section 6656 of the Internal Revenue Code of 1986 for any failure to make a deposit of any applicable employment taxes if the Secretary determines that such failure was due to the reasonable anticipation of the credit allowed under this section.

(j) REGULATIONS AND GUIDANCE.—The Secretary shall issue such forms, instructions, regulations, and guidance as are necessary to implement the purposes of this section, including with respect to the application of the credit under subsection (a) to third-party payors (including professional employer organizations, certified professional employer organizations, or agents under section 3504 of the Internal Revenue Code of 1986), including regulations or guidance allowing such payors to submit documentation necessary to substantiate the eligible employer status of employers that use such payors.

(k) APPLICATION.—This section shall only apply to calendar quarters during the first 5 calendar years beginning after the date of the enactment of this Act.

* Sec. 138518.—Treatment of financial guaranty insurance companies as qualifying insurance corporations under passive foreign investment company rules

(a) IN GENERAL.—Section 1297(f)(3) is amended by adding at the end the following new subparagraph:

"(C) SPECIAL RULES FOR FINANCIAL GUARANTY INSURANCE COMPANIES.—

"(i) IN GENERAL.—Notwithstanding subparagraphs (A)(ii) and (B), the applicable income liabilities of a financial guaranty insurance company shall include its unearned premium reserves if—"
"(i) such company is prohibited under generally accepted accounting principles from reporting on its applicable financial statements reserves for losses and loss adjustment expenses with respect to a financial guaranty insurance or reinsurance contract except to the extent that losses and loss adjustment expenses are expected to exceed the unearned premium reserves on the contract;

"(ii) the applicable financial statement of such company reports financial guaranty exposure of at least 15-to-1 or State or local bond exposure of at least 9-to-1 (8-to-1 in the case of a taxable year of such company which ends on or before December 31, 2018); and

"(iii) such company includes in its insurance liabilities only its unearned premium reserves relating to insurance written or assumed that is within the single risk limits set forth in subsection (D) of section 4 of the Financial Guaranty Insurance Guideline (modified by using total shareholder's equity as reported on the applicable financial statement of the company rather than aggregate of the surplus to policyholders and contingency reserves);

"(iv) APPLICATION OF ALTERNATIVE FACTS AND CIRCUMSTANCES TEST.—A financial guaranty insurance company shall be treated as satisfying the requirements of paragraph (2)(B):

"(iii) FINANCIAL GUARANTY INSURANCE COMPANY.—For purposes of this subparagraph, the term 'financial guaranty insurance company' means any insurance company the sole business of which is writing or reinsuring financial guaranty insurance (as defined in subsection (A) of section 4 of the Financial Guaranty Insurance Guideline) which is permitted under subsection (B) of section 4 of such Guideline.

"(iv) FINANCIAL GUARANTY EXPOSURE.—For purposes of this subparagraph, the term 'financial guaranty exposure' means the ratio of—

"(i) the net debt-service outstanding insured or reinsured by the company that is within the single risk limits set forth in the Financial Guaranty Insurance Guideline (as reported on such company's applicable financial statement); to

"(ii) the company's total assets (as so reported):

"(v) STATE OR LOCAL BOND EXPOSURE.—For purposes of this subparagraph, the term 'State or local bond exposure' means the ratio of—

"(i) the net unpaid principal of State or local bonds (as defined in section 403(2)(1)) insured or reinsured by the company that is within the single risk limits set forth in the Financial Guaranty Insurance Guideline (as reported on such company's applicable financial statement); to

"(ii) the company's total assets (as so reported)."

"(vi) FINANCIAL GUARANTY INSURANCE GUIDELINE.—For purposes of this subparagraph—

(1)
"(1) IN GENERAL.—The term 'Financial Guaranty Insurance Guideline' means the October 2008 model regulation that was adopted by the National Association of Insurance Commissioners on December 4, 2007.

"(2) DETERMINATIONS MADE BY SECRETARY.—The determination of whether any provision of the Financial Guaranty Insurance Guideline has been satisfied shall be made by the Secretary.

(b) REPORTING OF CERTAIN ITEMS.—
Section 1297(f)(4) is amended by adding at the end the following new subparagraph:

"(G) CLARIFICATION THAT CERTAIN ITEMS ON APPLICABLE FINANCIAL STATEMENT BE SEPARATELY REPORTED WITH RESPECT TO CORPORATION.—An amount described in paragraph (1)(B) or clause (i)(II), (i)(III), (iv)(I), (iv)(II), (v)(I), or (v)(II) of paragraph (3)(G) shall be treated as reported on an applicable financial statement for purposes of this section if—

"(i) such amount is separately reported on such statement with respect to the corporation referred to in paragraph (1), or

"(ii) such amount is separately determined for purposes of calculating an amount which is reported on such statement;

"(D) AUTHORITY OF SECRETARY TO REQUIRE REPORTING.—

"(1) IN GENERAL.—Each United States person who owns an interest in a specified non-publicly traded foreign corporation and who takes the position that such corporation is not a passive foreign investment company shall report to the Secretary such information with respect to such corporation as the Secretary may require.

"(2) SPECIFIED NON-PUBLICLY TRADED FOREIGN CORPORATION.—For purposes of this subparagraph, the term 'specified non-publicly traded foreign corporation' means any foreign corporation—

"(i) which would be a passive foreign investment company if subsection (b)
(2)(B) did not apply, and

"(ii) no interest in which is traded on an established securities market."

(e) EFFECTIVE DATE.—

(1) IN GENERAL.—Except as otherwise provided in this subsection, the amendments made by this section shall take effect as if included in section 14501 of Public Law 115-97.

(2) REPORTING.—The amendment made by subsection (b) shall apply to reports made after the date of the enactment of this Act.

* Sec. 138510. Credit for qualified access technology for the blind

(a) IN GENERAL—

Subpart G of part IV of subchapter A of chapter 1 is amended by inserting after section 38G the following new section:

"(i)
"Sec. 36H. Credit for qualified access technology for the blind"

(a) ALLOWANCE OF CREDIT.— There shall be allowed as a credit against the tax imposed by this subtitle an amount equal to amounts paid or incurred during the taxable year, not compensated for by insurance or otherwise, by the taxpayer for qualified access technology for use by a qualified blind individual who is the taxpayer, the taxpayer's spouse, or any dependent (as defined in section 152) of the taxpayer.

(b) LIMITATION.— The aggregate amount of the credit allowed under subsection (a) with respect to any qualified blind individual shall not exceed $2,000 in any 3-consecutive-taxable-year period.

c) DEFINITIONS.— For purposes of this section—

(1) QUALIFIED BLIND INDIVIDUAL.— The term "qualified blind individual" means an individual who is blind within the meaning of section 63(f)(4);

(2) QUALIFIED ACCESS TECHNOLOGY DEFINED.— The term "qualified access technology" means hardware, software, or other information technology the primary function of which is to convert or adapt information which is visually represented into forms or formats usable by blind individuals.

d) DENIAL OF DOUBLE BENEFIT.— No credit shall be allowed under subsection (a) for any expense for which a deduction or credit is allowed under any other provision of this chapter.

e) INFLATION ADJUSTMENT.—

(1) IN GENERAL.— In the case of a taxable year beginning after 2022, the $2,000 amount in subsection (b) shall be increased by an amount equal to—

(A) such dollar amount, multiplied by

(B) the cost-of-living adjustment determined under section 1(f)(3) for the calendar year in which the taxable year begins, determined by substituting "calendar year 2024" for "calendar year 2014" in subparagraph (A)(ii) thereof;

(2) ROUNDING.— If the amount as adjusted under subparagraph (A) is not a multiple of $100, such amount shall be rounded to the next-lowest multiple of $100.

(f) TERMINATION.— This section shall not apply with respect to amounts paid or incurred in taxable years beginning after December 31, 2026.

(b) CONFORMING AMENDMENTS:

(1) Section 6211(b)(4)(A), as amended by the preceding provisions of this Act, is amended by inserting "36H" after "36G".

(2) Section 1324(b)(2) of title 31, United States Code, is amended by inserting "36H" after "36G".

(3) The table of sections for subpart C of part IV of subchapter A is amended by inserting after the item relating to section 36G the following new item:

"Sec. 36H. Credit for qualified access technology for the blind."

(t): EFFECTIVE DATE.— The amendments made by this section shall apply to taxable years beginning after December 31, 2024.
Sec. 438520: Modification of REIT-Constructive Ownership Rules

(a) IN GENERAL—
Section 866(d)(5) is amended by striking "and" at the end of subparagraph (A), by striking the period at the end of subparagraph (B) and inserting ", and", and by adding at the end the following:

"(C) except as otherwise provided by the Secretary, stock, assets, and net profits constructively owned by a partnership, estate, trust, or corporation by reason of the application of section 318(a)(3) (after application of subparagraphs (A) and (B)) shall not be considered as owned by it for purposes of again applying such section in order to make another person the constructive owner of such stock, assets, or net profits."

Subparagraph (C) shall not prevent any person from being the constructive owner of stock, assets, or net profits of any person as the result of any other application of section 318(a) (as modified by this paragraph).

(b) EFFECTIVE DATE.—The amendments made by this section shall apply to taxable years ending after the date of the enactment of this Act.

(c) NO INFERENCE.—Nothing in this section or the amendments made by this section shall be construed to create any inference with respect to the proper application of section 318 of the Internal Revenue Code of 1986 to cases other than cases to which such amendments apply.

Subtitle J—Drug Pricing

Part I—Lowering Prices Through Fair Drug Price Negotiation

Sec. 439001: Providing for lower prices for certain high-priced single-source drugs

(a) PROGRAM TO LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE SOURCE DRUGS.—
Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended by adding at the end the following new part:

"Part E—Fair Price Negotiation Program to Lower Prices for Certain High-Priced Single-Source Drugs

Sec. 4491: Establishment of program

(a) IN GENERAL.—The Secretary shall establish a Fair Price Negotiation Program (in this part referred to as the ‘program’). Under the program, with respect to each price applicability period, the Secretary shall—

"(1) publish a list of selected drugs in accordance with section 4492;

"(2) enter into agreements with manufacturers of selected drugs with respect to such period, in accordance with section 4493;

"(3) negotiate and, if applicable, renegotiate maximum fair prices for such selected drugs, in accordance with section 4494; and

"(4) carry out the administrative duties described in section 4496;"
(b) Definitions relating to timing.—For purposes of this part:

(1) Initial price applicability year.—The term 'initial price applicability year' means a plan year (beginning with plan year 2025) or, if agreed to in an agreement under section 1193 by the Secretary and manufacturer involved, a period of more than one plan year (beginning on or after January 1, 2025).

(2) Price applicability period.—The term 'price applicability period' means, with respect to a drug, the period beginning with the initial price applicability year with respect to which such drug is a selected drug and ending with the last plan year during which the drug is a selected drug.

(3) Selected drug publication date.—The term 'selected drug publication date' means, with respect to each initial price applicability year, April 15 of the plan year that begins 2 years prior to such year.

(4) Voluntary negotiation period.—The term 'voluntary negotiation period' means, with respect to an initial price applicability year with respect to a selected drug, the period—

(A) beginning on the sooner of—

(i) the date on which the manufacturer of the drug and the Secretary enter into an agreement under section 1193 with respect to such drug; or

(ii) June 15 following the selected drug publication date with respect to such selected drug; and

(B) ending on March 31 of the year that begins one year prior to the initial price applicability year.

c) Other definitions.—For purposes of this part:

(1) Fair price eligible individual.—The term 'fair price eligible individual' means, with respect to a selected drug—

(A) in the case such drug is furnished or dispensed to the individual at a pharmacy or by a mail order service—

(i) an individual who is enrolled under a prescription drug plan under part D of title XVIII or an MA-PD plan under part C of such title if coverage is provided under such plan for such selected drug; and

(ii) an individual who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or dispensed; and

(B) in the case such drug is furnished or administered to the individual by a hospital, physician, or other provider of services or supplier—

(i) an individual who is entitled to benefits under part A of title XVIII or enrollee under part B of such title if such selected drug is covered under the respective part; and
"(ii) an individual who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or administered.

"(2) MAXIMUM FAIR PRICE.— The term 'maximum fair price' means, with respect to a plan-year during a price-applicability period and with respect to a selected drug (as defined in section 1192(o)) with respect to such period, the price published pursuant to section 1195 in the Federal Register for such drug and year.

"(3) AVERAGE INTERNATIONAL MARKET PRICE DEFINED.—

"(A) IN GENERAL.— The terms 'average international market price' and 'AIM price' mean, with respect to a drug, the average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for a unit (as defined in paragraph (4)) of the drug for sales of such drug (calculated across different dosage forms and strengths of the drug and net-based on the specific formulation or package size or package type), as computed (as of the date of publication of such drug as a selected drug under section 1192(a)) in all countries described in clause (ii) of subparagraph (B) that are applicable countries (as described in clause (i) of such subparagraph) with respect to such drug.

"(B) APPLICABLE COUNTRIES.—

"(i) IN GENERAL.— For purposes of subparagraph (A), a country described in clause (ii) is an applicable country described in this clause with respect to a drug if there is available an average price for any unit for the drug for sales of such drug in such country.

"(ii) COUNTRIES DESCRIBED.— For purposes of this paragraph, the following countries are described in this clause:

"(I) Australia;

"(II) Canada;

"(III) France;

"(IV) Germany;

"(V) Japan;

"(VI) The United Kingdom;

"(4) UNIT.— The term 'unit' means, with respect to a drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the drug that is dispensed.

"Sec. 1192. Selection of negotiation-eligible drugs as selected drugs

"(a) IN GENERAL.— Not later than the selected drug publication date with respect to an initial price applicability year, subject to subsection (b), the Secretary shall select and publish in the Federal Register a list of—

"(I)
4(A) with respect to an initial-price-applicability-year-during-2025, at least 25 negotiation-eligible drugs described in subparagraphs (A) and (B), but not subparagraph (C), of subsection (d)(1) or, with respect to an initial-price-applicability-year during such period beginning after 2025, the maximum number (if such number is less than 25) of such negotiation-eligible drugs for the year) with respect to such year; and

4(B) with respect to an initial-price-applicability-year during 2026 or a subsequent year, at least 50 negotiation-eligible drugs described in subparagraphs (A) and (B), but not subparagraph (C), of subsection (d)(1) or, with respect to an initial-price-applicability-year during such period, the maximum number (if such number is less than 50) of such negotiation-eligible drugs for the year) with respect to such year;

4(2) all negotiation-eligible drugs described in subparagraph (C) of such subsection with respect to such year; and

4(3) all new entrant negotiation-eligible drugs (as defined in subsection (g)(1)) with respect to such year.

Each drug published on the list pursuant to the previous sentence shall be subject to the negotiation process under section 1194 for the voluntary negotiation period with respect to such initial-price-applicability-year (and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period). In applying this subsection, any negotiation-eligible drug that is selected under this subsection for an initial-price-applicability-year shall not count toward the required minimum amount of drugs to be selected under paragraph (f) for any subsequent year, including such a drug so selected that is subject to renegotiation under section 1194.

4(b) Selection of drugs.—In carrying out subsection (a)(1) the Secretary shall select for inclusion on the published list described in subsection (a) with respect to a price applicability period, the negotiation-eligible drugs that the Secretary projects will result in the greatest savings to the Federal Government or fair price eligible individuals during the price applicability period. In making this projection of savings for drugs for which there is an AIM price for a price applicability period, the savings shall be projected across different dosage forms and strengths of the drugs and not based on the specific formulation or package-size or package-type of the drugs, taking into consideration both the volume of drugs for which payment is made, to the extent such data is available, and the amount by which the net price for the drugs exceeds the AIM price for the drugs.

4(c) Selected drug.—For purposes of this part, each drug included on the list published under subsection (a) with respect to an initial-price-applicability-year shall be referred to as a 'selected drug' with respect to each year and each subsequent plan year beginning after the first-plan year beginning after the date on which the Secretary determines two or more drug products—

4(1) are approved or licensed (as applicable)—

4(A) under section 505(j) of the Federal Food, Drug, and Cosmetic Act using such drug as the listed drug;
"(B) under section 351(k) of the Public Health Service Act using such drug as the reference product; and

"(2) continue to be marketed.

"(d) Negotiation-Eligible Drug.—

"(1) In General.—For purposes of this part, the term 'negotiation-eligible drug' means, with respect to the selected drug publication date with respect to an initial price applicability year, a qualifying single source drug, as defined in subsection (e), that meets any of the following criteria:

"(A) Covered Part D Drugs.—The drug is among the 125 covered part D drugs (as defined in section 1860D-2(e)) for which there was an estimated greatest net spending under parts C and D of title XVIII, as determined by the Secretary, during the most recent plan year prior to such drug publication date for which data are available.

"(B) Other Drugs.—The drug is among the 125 drugs for which there was an estimated greatest net spending in the United States (including the 50 States, the District of Columbia, and the territories of the United States), as determined by the Secretary, during the most recent plan year prior to such drug publication date for which data are available.

"(G) Insulin.—The drug is a qualifying single source drug described in subsection (e)(3).

"(2) Clarification.—In determining whether a qualifying single source drug satisfies any of the criteria described in paragraph (1), the Secretary shall, to the extent practicable, use data that is aggregated across dosage forms and strengths of the drug and not based on the specific formulation or package size or package type of the drug:

"(3) Publication.—Not later than the selected drug publication date with respect to an initial price applicability year, the Secretary shall publish in the Federal Register a list of negotiation-eligible drugs with respect to such selected drug publication date.

"(e) Qualifying Single Source Drug.—For purposes of this part, the term 'qualifying single source drug' means any of the following:

"(1) Drug Products.—A drug that

"(A) is approved under section 505(e) of the Federal Food, Drug, and Cosmetic Act and continues to be marketed pursuant to such approval; and

"(B) is not the listed drug for any drug that is approved and continues to be marketed under section 505(i) of such Act.

"(2) Biological Products.—A biological product that

"(A) is licensed under section 351(a) of the Public Health Service Act, including any product that has been deemed to be licensed under section 351 of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009; and continues to be marketed under section 351 of such Act; and

"(B) is not the reference product for any biological product that is licensed and continues to be marketed under section 351(k) of such Act.
"(3) INSULIN PRODUCT.—Notwithstanding paragraphs (1) and (2), any insulin product that is approved under subsection (c) or (f) of section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under subsection (e) or (i) of section 351 of the Public Health Service Act and continues to be marketed under such section 505 or 351, including any insulin product that has been deemed to be licensed under section 351(a) of the Public Health Service Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 and continues to be marketed pursuant to such license.

For purposes of applying paragraphs (1) and (2), a drug or biological product that is marketed by the same sponsor or manufacturer (or an affiliate thereof or a cross-licensed producer or distributor) as the listed drug or reference product described in such respective paragraph shall not be taken into consideration.

"(f) INFORMATION ON INTERNATIONAL DRUG PRICES.—For purposes of determining which negotiation-eligible drugs to select under subsection (e) and, in the case of such drugs that are selected drugs, to determine the maximum fair price for such a drug and whether such maximum fair price should be renegotiated under section 1194, the Secretary shall use data relating to the AIM price with respect to such drug as available or provided to the Secretary and shall on an ongoing basis request from manufacturers of selected drugs information on the AIM price of such a drug.

"(g) NEW ENTRANT NEGOTIATION-ELIGIBLE DRUGS.—

"(1) IN GENERAL.—For purposes of this part, the term ‘new entrant negotiation-eligible drug’ means, with respect to the selected drug publication date, with respect to an initial price applicability year, a qualifying single source drug—

"(A) that is first approved or licensed, as described in paragraph (1), (2), or (3) of subsection (e), as applicable, during the year preceding such selected drug publication date; and

"(B) that the Secretary determines under paragraph (2) is likely to be included as a negotiation-eligible drug with respect to the subsequent selected drug publication date.

"(2) DETERMINATION.—In the case of a qualifying single source drug that meets the criteria described in subparagraph (A) of paragraph (1), with respect to an initial price applicability year, if the wholesale acquisition cost at which such drug is first marketed in the United States is equal to or greater than the median household income (as determined according to the most recent data collected by the United States Census Bureau), the Secretary shall determine before the selected drug publication date, with respect to the initial price applicability year, if the drug is likely to be included as a negotiation-eligible drug with respect to the subsequent selected drug publication date, based on the projected spending under title XVIII of the United States on such drug. For purposes of this paragraph the term ‘United States’ includes the 50 States, the District of Columbia, and the territories of the United States.

"(h) CONFLICT-OF-INTEREST.—

"(1) IN GENERAL.—In the case the Inspector General of the Department of Health and Human Services determines the Secretary has a conflict, with respect to a matter
described in paragraph (2), the individual described in paragraph (3) shall carry out the duties of the Secretary under this part, with respect to a negotiation-eligible drug, that would otherwise be such a conflict.

"(2) MATTER DESCRIBED.—A matter described in this paragraph is—

"(A) a financial interest (as described in section 2635.402 of title 5, Code of Federal Regulations, as in effect on the date of the enactment of this section, except for an interest described in subsection (b)(2)(iv) of such section)) on the date of the selected drug publication date, with respect to the price-applicability year (as applicable);

"(B) a personal or business relationship (as described in section 2635.502 of such title) on the date of the selected drug publication date, with respect to the price-applicability year;

"(C) employment by a manufacturer of a negotiation-eligible drug during the preceding 10-year period beginning on the date of the selected drug publication date, with respect to each price-applicability year; and

"(D) any other matter the General Counsel determines appropriate.

"(3) INDIVIDUAL DESCRIBED.—An individual described in this paragraph is—

"(A) the highest-ranking officer or employee of the Department of Health and Human Services (as determined by the organizational chart of the Department) that does not have a conflict under this subsection; and

"(B) is nominated by the President and confirmed by the Senate with respect to the position.

"Sec. 1193. Manufacturer agreements

"(a) IN GENERAL.—For purposes of section 1191(a)(2), the Secretary shall enter into agreements with manufacturers of selected drugs with respect to a price-applicability period, by not later than June 15 following the selected drug publication date, with respect to such selected drug, under which—

"(1) during the voluntary negotiation period for the initial price-applicability year for the selected drug, the Secretary and manufacturer, in accordance with section 1194, negotiate to determine (and, by not later than the last date of such period and in accordance with subsection (c), agree to) a maximum fair price for such selected drug of the manufacturer in order to provide access to such price—

"(A) to fair-price eligible individuals who with respect to such drug are described in subparagraph (A) of section 1191(c)(1) and are furnished or dispensed such drug during, subject to subparagraph (2), the price-applicability period; and

"(B) to hospitals, physicians, and other providers of services and suppliers with respect to fair-price eligible individuals who with respect to such drug are described in subparagraph (B) of such section and are furnished or administered such drug during, subject to subparagraph (2), the price-applicability period;
(2) the Secretary and the manufacturer shall, in accordance with a process and during a period specified by the Secretary pursuant to rulemaking, renegotiate (and, by not later than the last date of such period and in accordance with subsection (c), agree to) the maximum fair price for such drug if the Secretary determines that there is a material change in any of the factors described in section 1194(d) relating to the drug, including changes in the AIM price for such drug, in order to provide access to such maximum fair price (as so renegotiated).

(A) to fair price eligible individuals who with respect to such drug are described in subparagraph (A) of section 1194(c)(1) and are furnished or dispensed such drug during any year during the price applicability period (beginning after such renegotiation) with respect to such selected drug; and

(B) to hospitals, physicians, and other providers of services and suppliers with respect to fair price eligible individuals who with respect to such drug are described in subparagraph (B) of such section and are furnished or administered such drug during any year described in subparagraph (A);

(3) the maximum fair price (including as renegotiated pursuant to paragraph (2)), with respect to such a selected drug, shall be provided to fair price eligible individuals, who with respect to such drug are described in subparagraph (A) of section 1194(c)(1); at the pharmacy or by a mail order service at the point-of-sale of such drug;

(4) the manufacturer, subject to subsection (d), submits to the Secretary, in a form and manner specified by the Secretary—

(A) for the voluntary negotiation period for the price applicability period (and, if applicable, before any period of renegotiation specified pursuant to paragraph (2)) with respect to such drug, all information that the Secretary requires to carry out the negotiation (or renegotiation process) under this part, including information described in section 1192(f) and section 1194(d)(1); and

(B) on an ongoing basis, information on changes in prices for such drug that would affect the AIM price for such drug or otherwise provide a basis for renegotiation of the maximum fair price for such drug pursuant to paragraph (2);

(5) the manufacturer agrees that in the case the selected drug of a manufacturer is a drug described in subsection (c), the manufacturer will, in accordance with such subsection, make any payment required under such subsection with respect to such drug; and

(6) the manufacturer complies with requirements imposed by the Secretary for purposes of administering the program, including with respect to the duties described in section 1196;

(b) AGREEMENT IN EFFECT UNTIL DRUG IS NO LONGER A SELECTED DRUG. An agreement entered into under this section shall be effective, with respect to a drug, until such drug is no longer considered a selected drug under section 1192(c).

(c) SPECIFIC RULE FOR CERTAIN SELECTED DRUGS WITHOUT AIM PRICE. In general— In the case of a selected drug for which there is no AIM price available with respect to the initial price applicability year for such drug and for which an
AIM price becomes available beginning with respect to a subsequent plan year during the price-applicability period for such drug, if the Secretary determines that the amount described in paragraph (2)(A) for a unit of such drug is greater than the amount described in paragraph (2)(B) for a unit of such drug; then by not later than one year after the date of such determination, the manufacturer of such selected drug shall pay to the Treasury an amount equal to the product of—

"(A) the difference between such amount described in paragraph (2)(A) for a unit of such drug and such amount described in paragraph (2)(B) for a unit of such drug; and

"(B) the number of units of such drug sold in the United States, including the 50 States, the District of Columbia, and the territories of the United States, during the period described in paragraph (2)(B).

"(2) AMOUNT DESCRIBED—

"(A) WEIGHTED AVERAGE PRICE BEFORE AIM PRICE AVAILABLE.—For purposes of paragraph (1), the amount described in this subparagraph for a selected drug described in such paragraph is the amount equal to the weighted-average manufacturer price (as defined in section 1927(k)(1)) for such dosage strength and form for the drug during the period beginning with the first plan year for which the drug is included on the list of negotiation-eligible drugs published under section 1492(d) and ending with the last plan year during the price-applicability period for such drug with respect to which there is no AIM price available for such drug.

"(B) AMOUNT MULTIPLIER AFTER AIM PRICE AVAILABLE.—For purposes of paragraph (1), the amount described in this subparagraph for a selected drug described in such paragraph is the amount equal to 200 percent of the AIM price for such drug with respect to the first plan year during the price-applicability period for such drug with respect to which there is an AIM price available for such drug.

"(d) CONFIDENTIALITY OF INFORMATION.—Information submitted to the Secretary under this part by a manufacturer of a selected drug that is proprietary information of such manufacturer (as determined by the Secretary) may be used only by the Secretary or disclosed to and used by the Comptroller General of the United States or the Medicare Payment Advisory Commission for purposes of carrying out this part.

"(e) REGULATIONS—

"(1) IN GENERAL.—The Secretary shall, pursuant to rulemaking, specify, in accordance with paragraph (2), the information that must be submitted under subsection (a)(4).

"(2) INFORMATION SPECIFIED.—Information described in paragraph (1), with respect to a selected drug, shall include information on sales of the drug (by the manufacturer of the drug or by another entity under license or other agreement with the manufacturer, with respect to the sales of such drug, regardless of the name under which the drug is sold) in any foreign country that is part of the AIM price. The Secretary shall verify, to the extent practicable, such sales from appropriate officials of the government of the foreign country involved.
(f) COMPLIANCE WITH REQUIREMENTS FOR ADMINISTRATION OF PROGRAM.—Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under section 1196(e)(1), as applicable, for purposes of administering the program.

Sec. 4194. Negotiation and renegotiation process

(a) In general.—For purposes of this part, under an agreement under section 1193 between the Secretary and a manufacturer of a selected drug, with respect to the period for which such agreement is in effect and in accordance with subsections (b) and (c), the Secretary and the manufacturer—

(1) shall during the voluntary negotiation period with respect to the initial-price applicability year for such drug, in accordance with this section, negotiate a maximum fair price for such drug for the purpose described in section 1193(e)(1); and

(2) as applicable pursuant to section 1193(a)(2) and in accordance with the process specified pursuant to such section, renegotiate such maximum fair price for such drug for the purpose described in such section.

(b) Negotiating methodology and objective.—

(1) In general.—The Secretary shall develop and use a consistent methodology for negotiations under subsection (a) that, in accordance with paragraph (2) and subject to paragraph (3), achieves the lowest maximum fair price for each selected drug while appropriately rewarding innovation.

(2) Prioritizing factors.—In considering the factors described in subsection (d) in negotiating (and, as applicable, renegotiating) the maximum fair price for a selected drug, the Secretary shall, to the extent practicable, consider all of the available factors listed but shall prioritize the following factors:

(A) Research and development costs.—The factor described in paragraph (1)(A) of subsection (d):

(B) Market data.—The factor described in paragraph (1)(B) of such subsection:

(C) Unit costs of production and distribution.—The factor described in paragraph (1)(C) of such subsection:

(D) Comparison to existing therapeutic alternatives.—The factor described in paragraph (2)(A) of such subsection:

(3) Requirement.—

(A) In general.—In negotiating the maximum fair price of a selected drug, with respect to an initial-price applicability year for the selected drug, and, as applicable, in renegotiating the maximum fair price for such drug, with respect to a subsequent year during the price-applicability period for such drug, in the case that the manufacturer of the selected drug offers under the negotiation or renegotiation, as applicable, a price for such drug that is not more than the target price described in subparagraph (B) for such drug for the respective year, the Secretary shall agree
under such negotiation or renegotiation, respectively, to such offered price as the maximum fair price.

"(B) TARGET PRICE.—

"(1) IN GENERAL.— Subject to clause (ii), the target price described in this subparagraph for a selected drug with respect to a year, is the average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for a unit of such drug for sales of such drug, as computed (across different dosage forms and strengths of the drug and not based on the specific formulation or package size or package type of the drug) in the applicable country described in section 1101(e)(3)(B) with respect to such drug that, with respect to such year, has the lowest average price for such drug as compared to the average prices (as so computed) of such drug with respect to such year in the other applicable countries described in such section with respect to such drug.

"(ii) SELECTED DRUGS WITHOUT AIM PRICE.— In applying this paragraph in the case of negotiating the maximum fair price of a selected drug for which there is no AIM price available with respect to the initial price applicability year for such drug, or, as applicable, renegotiating the maximum fair price for such drug with respect to a subsequent year during the price applicability period for such drug before the first plan year for which there is an AIM price available for such drug, the target price described in this subparagraph for such drug and respective year is the amount that is 80 percent of the average manufacturer price (as defined in section 1927(k)(1)) for such drug and year.

"(c) LIMITATION.—

"(1) IN GENERAL.— Subject to paragraph (2), the maximum fair price—negotiated (including as renegotiated) under this section for a selected drug, with respect to each plan year during a price applicability period for such drug, shall not exceed 120 percent of the AIM price applicable to such drug with respect to such year.

"(2) SELECTED DRUGS WITHOUT AIM PRICE.— In the case of a selected drug for which there is no AIM price available with respect to the initial price applicability year for such drug, for each plan year during the price applicability period before the first plan year for which there is an AIM price available for such drug, the maximum fair price—negotiated (including as renegotiated) under this section for the selected drug shall not exceed the amount equal to 85 percent of the average manufacturer price for the drug with respect to such year.

"(d) CONSIDERATIONS.— For purposes of negotiating and, as applicable, renegotiating (including for purposes of determining whether to renegotiate) the maximum fair price of a selected drug under this part with the manufacturer of the drug, the Secretary, consistent with subsection (b)(2), shall take into consideration the factors described in paragraphs (1), (2), (3), and (5), and may take into consideration the factors described in paragraph (4):

"(4) MANUFACTURER SPECIFIC INFORMATION.— The following information, including as submitted by the manufacturer:
"(A) Research and development costs of the manufacturer for the drug and the extent to which the manufacturer has recouped research and development costs.

"(B) Market data for the drug, including the distribution of sales across different programs and purchasers and projected future revenues for the drug.

"(C) Unit costs of production and distribution of the drug.

"(D) Prior Federal financial support for novel therapeutic discovery and development with respect to the drug.

"(E) Data on patents and on existing and pending exclusivity for the drug.

"(F) National sales data for the drug.

"(G) Information on clinical trials for the drug in the United States or in applicable countries described in section 4194(e)(3)(B):

"(2) INFORMATION ON ALTERNATIVE PRODUCTS.— The following information:

"(A) The extent to which the drug represents a therapeutic advance as compared to existing therapeutic alternatives and, to the extent such information is available, the costs of such existing therapeutic alternatives.

"(B) Information on approval by the Food and Drug Administration of alternative drug products.

"(C) Information on comparative effectiveness analysis for such products, taking into consideration the effects of such products on specific populations, such as individuals with disabilities, the elderly, terminally ill, children, and other patient populations.

In considering information described in subparagraph (C), the Secretary shall not use evidence or findings from comparative clinical effectiveness research in a manner that treats extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life of an individual who is younger, nondisabled, or not terminally ill. Nothing in the previous sentence shall affect the application or consideration of an AIM price for a selected drug.

"(3) FOREIGN SALES INFORMATION.— To the extent available on a timely basis, including as provided by a manufacturer of the selected drug or otherwise, information on sales of the selected drug in each of the countries described in section 4191(e)(3)(B):

"(4) VA DRUG PRICING INFORMATION.— Information disclosed to the Secretary pursuant to subsection (f).

"(5) ADDITIONAL INFORMATION.— Information submitted to the Secretary, in accordance with a process specified by the Secretary, by other parties that are affected by the establishment of a maximum fair price for the selected drug.

"(e) REQUEST FOR INFORMATION.— For purposes of negotiating and, as applicable, renegotiating (including for purposes of determining whether to renegotiate) the maximum fair price of a selected drug under this part with the manufacturer of the drug, with respect to a price applicability period, and other relevant data for purposes of this section—

"(f) the Secretary shall, not later than the selected drug publication date with respect to the initial price applicability year of such period, request drug pricing information from
the manufacturer of such selected drug, including information described in subsection (d) (4); and

"(2) by not later than October 1 following the selected drug publication date, the manufacturer of such selected drug shall submit to the Secretary such requested information in such form and manner as the Secretary may require.

The Secretary shall request, from the manufacturer or others, such additional information as may be needed to carry out the negotiation and renegotiation process under this section:

"(f) Disclosure of Information.—For purposes of this part, the Secretary of Veterans Affairs may disclose to the Secretary of Health and Human Services the price of any negotiation-eligible drug that is purchased pursuant to section 8126 of title 38, United States Code:

"Sec. 1105. Publication of maximum fair prices

"(a) In general.—With respect to an initial price applicability year and selected drug with respect to such year, not later than April 1 of the plan year prior to such initial price applicability year, the Secretary shall publish in the Federal Register the maximum fair price for such drug negotiated under this part with the manufacturer of such drug:

"(b) Updates.—

"(1) Subsequent-year maximum fair prices.—For a selected drug, for each plan year subsequent to the initial price applicability year for such drug with respect to which an agreement for such drug is in effect under section 1103, the Secretary shall publish in the Federal Register—

"(A) subject to subparagraph (B), the amount equal to the maximum fair price published for such drug for the previous year, increased by the annual percentage increase in the consumer price index for all urban consumers (all items; U.S. city average) as of September of such previous year, or

"(B) in the case the maximum fair price for such drug was renegotiated, for the first year for which such price as so renegotiated applies, such renegotiated maximum fair price.

"(2) Prices negotiated after deadline.—In the case of a selected drug with respect to an initial price applicability year for which the maximum fair price is determined under this part after the date of publication under this section, the Secretary shall publish such maximum fair price in the Federal Register by not later than 30 days after the date such maximum price is so determined:

"Sec. 1196. Administrative duties; coordination provisions

"(a) Administrative duties.—

"(4) In general.—For purposes of section 1194, the administrative duties described in this section are the following:

"(A) The establishment of procedures (including through agreements with manufacturers under this part) contracts with prescription drug plans under part D of title XVIII and MA–PD plans under part C of such title, and agreements under section
4197—with group health plans and health insurance issuers of health insurance coverage offered in the individual or group market under which the maximum fair price for a selected drug is provided to fair price eligible individuals, who with respect to such drug are described in subparagraph (A) of section 1191(c)(1); to pharmacies or by mail order service at the point of sale of the drug for the applicable price period for such drug and providing that such maximum fair price is used for determining cost-sharing under such plans or coverage for the selected drug.

(B) The establishment of procedures (including through agreements with manufacturers under this part and contracts with hospitals, physicians, and other providers of services and suppliers and agreements under section 1197 with group health plans and health insurance issuers of health insurance coverage offered in the individual or group market under which, in the case of a selected drug furnished or administered by such a hospital, physician, or other provider of services or supplier to fair price eligible individuals (who with respect to such drug are described in subparagraph (B) of section 1191(c)(1)), the maximum fair price for the selected drug is provided to such hospitals, physicians, and other providers of services and suppliers (as applicable) with respect to such individuals and providing that such maximum fair price is used for determining cost-sharing under the respective part, plan, or coverage for the selected drug.

(C) The establishment of procedures (including through agreements and contracts described in subparagraphs (A) and (B)) to ensure that, not later than 90 days after the dispensing of a selected drug to a fair price eligible individual by a pharmacy or mail order service, the pharmacy or mail order service is reimbursed for an amount equal to the difference between—

(i) the lesser of—

(ii) the wholesale acquisition cost of the drug;
(iii) the national average drug acquisition cost of the drug; and
(iv) any other similar determination of pharmacy acquisition costs of the drug as determined by the Secretary; and
(ii) the maximum fair price for the drug;

(D) The establishment of procedures to ensure that the maximum fair price for a selected drug is applied before—

(i) any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of fair price eligible individuals as the Secretary may specify; and
(ii) any other discounts;

(E) The establishment of procedures to enter into appropriate agreements and protocols for the ongoing computation of AIM prices for selected drugs, including, to the extent possible, to compute the AIM price for selected drugs and including by providing that the manufacturer of such a selected drug should provide information
for such computation not later than 3 months after the first date of the voluntary negotiation period for such selected drug:

"(F) The establishment of procedures to compute and apply the maximum fair price across different strength and dosage forms of a selected drug and not based on the specific formulation or package size or package type of the drug:

"(G) The establishment of procedures to negotiate and apply the maximum fair price in a manner that does not include any dispensing or similar fee:

"(H) The establishment of procedures to carry out the provisions of this part, as applicable, with respect to—

"(i) fair price eligible individuals who are enrolled under a prescription drug plan under part D of title XVIII or an MA-PD plan under part C of such title;

"(ii) fair price eligible individuals who are enrolled under a group health plan or health insurance coverage offered by a health insurance issuer in the individual or group market with respect to which there is an agreement in effect under section 1197, and

"(iii) fair price eligible individuals who are entitled to benefits under part A of title XVIII or enrolled under part B of such title.

"(I) The establishment of a negotiation process and renegotiation process in accordance with section 1194, including a process for acquiring information described in subsection (d) of such section and determining amounts described in subsection (b) of such section:

"(J) The provision of a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, fair price eligible individuals, and the third party with a contract under subsection (c)(1):

42. Monitoring Compliance:

"(A) In General.—The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under section 1193, including by establishing a mechanism through which violations of such terms may be reported:

"(B) Notification.—If a third party with a contract under subsection (c)(1) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such noncompliance for appropriate enforcement under section 4192 of the Internal Revenue Code of 1986 or section 1198, as applicable.

4(b) Collection of Data:

"(1) From Prescription Drug Plans and MA-PD Plans.—The Secretary may collect appropriate data from prescription drug plans under part D of title XVIII and MA-PD plans under part C of such title in a timeframe that allows for maximum fair prices to be provided under this part for selected drugs:

"(2) From Health Plans.—The Secretary may collect appropriate data from group health plans or health insurance issuers offering group or individual health insurance
coverage in a timeframe that allows for maximum fair prices to be provided under this part for selected drugs:

"(3) COORDINATION OF DATA COLLECTION.—To the extent feasible, as determined by the Secretary, the Secretary shall ensure that data collected pursuant to this subsection is coordinated with, and not duplicative of, other Federal data collection efforts;

"(e) CONTRACT WITH THIRD PARTIES.—

"(1) IN GENERAL.—The Secretary may enter into a contract with one or more third parties to administer the requirements established by the Secretary in order to carry out this part. At a minimum, the contract with a third party under the preceding sentence shall require that the third party—

"(A) receive and transmit information between the Secretary, manufacturers, and other individuals or entities the Secretary determines appropriate;

"(B) receive, distribute, or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to meet the obligations of manufacturers under agreements under this part;

"(C) provide adequate and timely information to manufacturers, consistent with the agreement with the manufacturer under this part, as necessary for the manufacturer to fulfill its obligations under this part; and

"(D) permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program;

"(2) PERFORMANCE REQUIREMENTS.—The Secretary shall establish performance requirements for a third party with a contract under paragraph (1) and safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this part:

"Sec. 1197. Voluntary participation by other health plans

"(e) AGREEMENT TO PARTICIPATE UNDER PROGRAM.—

"(1) IN GENERAL.—Subject to paragraph (2), under the program under this part the Secretary shall be treated as having in effect an agreement with a group health plan or health insurance issuer offering group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act), with respect to a price applicability period and a selected drug with respect to such period—

"(A) with respect to such selected drug furnished or dispensed at a pharmacy or by mail-order service if coverage is provided under such plan or coverage during such period for such selected drug as so furnished or dispensed; and

"(B) with respect to such selected drug furnished or administered by a hospital, physician, or other provider of services or supplier if coverage is provided under such plan or coverage during such period for such selected drug as so furnished or administered:

(I)
(2) Omitting Out of Agreement.— The Secretary shall not be treated as having in
effect an agreement under the program under this part with a group health-plan or health
insurance issuer offering group or individual health-insurance coverage with respect to a
price-applicability period and a selected drug with respect to such period if such a plan or
issuer affirmatively elects, through a process specified by the Secretary, not to participate
under the program with respect to such period and drug.

(b) Publication of Election.— With respect to each price-applicability period and each
selected drug with respect to such period, the Secretary and the Secretary of Labor and the
Secretary of the Treasury, as applicable, shall make public a list of each group health-plan and
each health-insurance issuer offering group or individual health-insurance coverage, with
respect to which coverage is provided under such plan or coverage for such drug, that has
elected under subsection (a) not to participate under the program with respect to such period
and drug.

Sec. 1198. Civil monetary penalty

(a) Violations relating to offering of maximum fair price.— Any manufacturer of a
selected drug that has entered into an agreement under section 1193, with respect to a plan
year during the price-applicability period for such drug, that does not provide access to a price
that is not more than the maximum fair price (or a lesser price) for such drug for such year—

(1) to a fair-price eligible individual who with respect to such drug is described in
subparagraph (A) of section 1191(c)(1) and who is furnished or dispensed such drug
during such year; or

(2) to a hospital, physician, or other provider of services or supplier with respect to
fair-price eligible individuals who with respect to such drug is described in subparagraph
(B) of such section and is furnished or administered such drug by such hospital,
physician, or provider or supplier during such year;

shall be subject to a civil monetary penalty equal to ten times the amount equal to the
difference between the price for such drug made available for such year by such manufacturer
with respect to such individual or hospital, physician, provider, or supplier and the maximum
fair price for such drug for such year.

(b) Violations of certain terms of agreement.— Any manufacturer of a selected
drug that has entered into an agreement under section 1193, with respect to a plan year
during the price-applicability period for such drug, that is in violation of a requirement imposed
pursuant to section 1193(a)(6) shall be subject to a civil monetary penalty of not more than
$1,000,000 for each such violation.

(c) Application.— The provisions of section 1128A (other than subsections (a) and (b))
shall apply to a civil monetary penalty under this section in the same manner as such
provisions apply to a penalty or proceeding under section 1128A(a).

Sec. 1199. Miscellaneous provisions

(a) Pappwork Reduction Act.— Chapter 35 of title 44, United States Code, shall not
apply to data collected under this part.
(b) LIMITATION ON JUDICIAL REVIEW.— The following shall not be subject to judicial review:

("(1) The selection of drugs for publication under section 1192(e);

("(2) The determination of whether a drug is a negotiation-eligible drug under section 1492(d);

("(3) The determination of the maximum fair price of a selected drug under section 1494;

("(4) The determination of units of a drug for purposes of section 1194(c)(3);

"(c) COORDINATION.— In carrying out this part with respect to group health plans or health insurance coverage offered in the group market that are subject to oversight by the Secretary of Labor or the Secretary of the Treasury, the Secretary of Health and Human Services shall coordinate with such respective Secretary.

"(d) DATA-SHARING.— The Secretary shall share with the Secretary of the Treasury such information as is necessary to determine the tax imposed by section 4492 of the Internal Revenue Code of 1986.

(b) APPLICATION OF MAXIMUM FAIR PRICES AND CONFORMING AMENDMENTS.—

(1) UNDER MEDICARE.—

(A) APPLICATION TO PAYMENTS UNDER PART B.— Section 1847A(b)(1)(B) of the Social Security Act (42 U.S.C. 1395w-3a(b)(1)(B)) is amended by inserting "or in the case of such a drug or biological that is a selected drug (as defined in section 1492(e)), with respect to a price applicable period (as defined in section 1191(b)(2)); 106 percent of the maximum fair price (as defined in section 1191(c)(2)) applicable for such drug and a plan year during such period" after "paragraph (4)".

(B) EXCEPTION TO PART D NON-INTERFERENCE.— Section 1860D-11(i) of the Social Security Act (42 U.S.C. 1395w-111(i)) is amended by inserting ", except as provided under part E of title XVIII after "the Secretary".

(C) APPLICATION AS NEGOTIATED PRICE UNDER PART D.— Section 1860D-2(d)(4) of the Social Security Act (42 U.S.C. 1395w-102(d)(4)) is amended—

(i) in subparagraph (B), by inserting ", subject to subparagraph (D)," after "negotiated prices"; and

(ii) by adding at the end the following new subparagraph:

"(D) APPLICATION OF MAXIMUM FAIR PRICE FOR SELECTED DRUGS.— In applying this section, in the case of a covered part D drug that is a selected drug (as defined in section 1192(e)), with respect to a price applicable period (as defined in section 1191(b)(2)), the negotiated prices used for payment (as described in this subsection) shall be the maximum fair price (as defined in section 1191(c)(2)) for such drug and for each plan year during such period.".

(2) INFORMATION FROM PRESCRIPTION DRUG PLANS AND MA-PD PLANS KEPT REB.

(i) PRESCRIPTION DRUG PLANS.
Section 1860D-12(b) of the Social Security Act (42 U.S.C. 1395w-112(b)) is amended by adding at the end the following new paragraph:

"(b) Provision of information related to maximum fair prices.—
Each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan offered by such sponsor shall require the sponsor to provide information to the Secretary, as requested by the Secretary in accordance with section 1419(b)."

(ii) MA–PD plans—
Section 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w-27(f)(3)) is amended by adding at the end the following new subparagraph:

"(E) Provision of information related to maximum fair prices.—
Section 1860D-12(b)(6)."

(2) Under group health plans and health insurance coverage—

(A) PHSA—
Part D of title XXVII of the Public Health Service Act (42 U.S.C. 300gg-11 et seq.) is amended by adding at the end the following new section:

"Sec. 2799A–11. Fair Price Negotiation Program and application of maximum fair prices.

(a) In general.—In the case of a group health plan or health insurance issuer offering group or individual health insurance coverage that is treated under section 4107 of the Social Security Act as having in effect an agreement with the Secretary under the Fair Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 4104(b) of such Act) and a selected drug (as defined in section 4102(c) of such Act) with respect to such period, with respect to which coverage is provided under such plan or coverage—

"(1) the provisions of such part shall apply—

"(A) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or dispensed at a pharmacy or by mail order service, to the plans or coverage offered by such plan or issuer, and to the individuals enrolled under such plans or coverage, during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA–PD plans, and to individuals enrolled under such prescription drug plans and MA–PD plans during such period; and

"(B) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier, to the plans or coverage offered by such plan or issuer, to the individuals enrolled under such plans or coverage, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary, to individuals entitled to benefits"
under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period:

"(2) the plan or issuer shall apply any cost-sharing responsibilities under such plan or coverage, with respect to such selected drug, by substituting an amount not more than the maximum price negotiated under part E of title XI for such drug in lieu of the drug price upon which the cost-sharing would have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and

"(3) the Secretary shall apply the provisions of such part E to such plan, issuer, and coverage, such individuals so enrolled in such plans and coverage, and such hospitals, physicians, and other providers and suppliers participating in such plans and coverage;

"(b) Notification regarding nonparticipation in Fair Price Negotiation Program.—A group health plan or a health insurance issuer offering group or individual health insurance coverage shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1197 of the Social Security Act by the plan or issuer to not participate in the Fair Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act), for which coverage is provided under such plan or coverage before the beginning of the plan year for which such election was made.

(B) ERISA.—

(i) IN GENERAL.—

Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1181 et seq.) is amended by adding at the end the following new section:

"Sec. 726. Fair Price Negotiation Program and application of maximum fair prices

"(a) IN GENERAL.—In the case of a group health plan or health insurance issuer offering group health insurance coverage that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary under the Fair Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period with respect to which coverage is provided under such plan or coverage—

"(1) the provisions of such part shall apply, as applicable—

"(A) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or dispensed at a pharmacy or by a mail order service, to the plans or coverage offered by such plan or issuer, and to the individuals enrolled under such plans or coverage;"
during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA-PD plans, and to individuals enrolled under such prescription drug plans and MA-PD plans during such period; and

"(B) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier to the plans or coverage offered by such plan or issuers, to the individuals enrolled under such plan or coverage, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug, in the same manner as such provisions apply to the Secretary, to individuals entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period;

"(2) the plan or issuer shall apply any cost-sharing responsibilities under such plan or coverage, with respect to such selected drug, by substituting an amount not more than the maximum fair price negotiated under such part E of title XI for such drug in lieu of the drug price upon which the cost-sharing would have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and

"(3) the Secretary shall apply the provisions of such part E to such plan, issuer, and coverage, and such individuals so enrolled in such plans:

"(b) Notification regarding nonparticipation in Fair-Price Negotiation Program.—A group health plan or a health insurance issuer offering group health insurance coverage shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1192 of the Social Security Act by the plan or issuer to not participate in the Fair-Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act) for which coverage is provided under such plan or coverage before the beginning of the plan year for which such election was made.

(ii) Application to retiree and certain small group health plans.—Section 792(a) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1191a(a)) is amended by striking "section 741" and inserting "sections 741 and 726".

(iii) Clerical amendment.—The table of sections for subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 is amended by adding at the end the following:

"Sec. 726. Fair-Price Negotiation Program and application of maximum fair
The text of the document provided is partially visible due to the cropping. Here is the readable section:

"Sec. 9826. Fair-Price Negotiation Program and application of maximum fair prices

(a) In general.—In the case of a group health plan that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary under the Fair-Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period, with respect to which coverage is provided under such plan—

(1) the provisions of such part shall apply, as applicable—

(A) if coverage of such selected drug is provided under such plan if the drug is furnished or dispensed at a pharmacy or by a mail-order service, to the plan, and to the individuals enrolled under such plan during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA-PD plans, and to individuals enrolled under such prescription drug plans and MA-PD plans during such period; and

(B) if coverage of such selected drug is provided under the plan, if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier, to the plan, to the individuals enrolled under such plan, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary, to individuals entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period;

(2) the plan shall apply any cost-sharing responsibilities under such plan, with respect to such selected drug, by substituting an amount not more than the maximum fair-price negotiated under such part E of title XI for such drug in lieu of the drug price, upon which the cost-sharing would have otherwise been applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and

(3) the Secretary shall apply the provisions of such part E to such plan and such individuals so enrolled in such plan:
"(b) Notification regarding nonparticipation in Fair Price Negotiation Program.—A group health plan shall publicly disclose in a manner and in accordance with a process specified by the Secretary—any election made under section 1197 of the Social Security Act by the plan to not participate in the Fair Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act) for which coverage is provided under such plan before the beginning of the plan year for which such election was made."

(ii) Application to retiree and certain small group health plans.—Section 9821(a)(2) of the Internal Revenue Code of 1986 is amended by inserting "other than with respect to section 9828," before "any group health plan."

(iii) Clerical amendment.—The table of sections for subchapter B of chapter 110 of such Code is amended by adding at the end the following new item:

"Sec. 9826. Fair Price Negotiation Program and application of maximum fair prices."

(3) Fair price negotiation program—prices included in best price and AMP.—Section 1927 of the Social Security Act (42 U.S.C. 1396d-8) is amended—

(A) in subsection (c)(1)(C)(ii)—

(i) in subclause (III), by striking at the end "; and";

(ii) in subclause (IV), by striking at the end the period and inserting "; and";

and

(iii) by adding at the end the following new subclause:

"(V) in the case of a rebate period and a covered outpatient drug that is a selected drug (as defined in section 1192(c)) during such rebate period, shall be inclusive of the price for such drug made available from the manufacturer during the rebate period by reason of application of part E of title XI to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States."; and

(B) in subsection (k)(1)(B), by adding at the end the following new clause:

"(iii) Clarification.—Notwithstanding clause (i), in the case of a rebate period and a covered outpatient drug that is a selected drug (as defined in section 1192(c)) during such rebate period, any reduction in price paid during the rebate period to the manufacturer for the drug by a wholesaler or retail community pharmacy described in subparagraph (A) by reason of application of part E of title XI shall be included in the average manufacturer price for the covered outpatient drug."
(4) FEHBP.—Section 8902 of title 5, United States Code, is amended by adding at
the end the following:

"(p) A contract may not be made or a plan approved under this chapter with any
carrier that has affirmatively elected, pursuant to section 1197 of the Social-Security Act,
not to participate in the Fair-Price Negotiation Program established under section 1191 of
such Act for any selected drug (as that term is defined in section 1192(c) of such Act).

(5) OPTION OF SECRETARY OF VETERANS AFFAIRS TO PURCHASE COVERED DRUGS AT
MAXIMUM FAIR PRICES.—Section 8126 of title 38, United States Code, is amended—
(A) in subsection (a)(2), by inserting "subject to subsection (j)," after "may not exceed";
(B) in subsection (d), in the matter preceding paragraph (4), by inserting "subject to
subsection (j) after "for the procurement of the drug"; and
(C) by adding at the end the following new subsection:

"(j)"

"(1) In the case of a covered drug that is a selected drug, for any year
during the price-applicability period for such drug, if the Secretary determines
that the maximum fair price of such drug for such year is less than the price for
such drug otherwise in effect pursuant to this section (including after application
of any reduction under subsection (a)(2) and any discount under subsection (e));
at the option of the Secretary, in lieu of the maximum price (determined after
application of the reduction under subsection (a)(2) and any discount under
subsection (e), as applicable) that would be permitted to be charged during such
year for such drug pursuant to this section without application of this subsection,
the maximum price permitted to be charged during such year for such drug
pursuant to this section shall be such maximum fair price for such drug and year.

(2) For purposes of this subsection:

(A) The term 'maximum fair price' means, with respect to a selected
drug and year during the price-applicability period for such drug, the
maximum fair price (as defined in section 1191(c)(2) of the Social-Security
Act) for such drug and year.

(B) The term 'negotiation-eligible drug' has the meaning given such
term in section 1192(d)(1) of the Social-Security Act.

(C) The term 'price-applicability period' has, with respect to a selected
drug, the meaning given such term in section 1191(b)(2) of such Act.

(D) The term 'selected drug' means, with respect to a year, a drug that
is a selected drug under section 1192(c) of such Act for such year."
Subchapter E of chapter 32 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:

"Sec. 4192. Selected drugs during noncompliance periods

(a) In general.—There is hereby imposed on the sale by the manufacturer, producer, or importer of any selected drug during a day described in subsection (b) a tax in an amount such that the applicable percentage is equal to the ratio of—

(1) such tax, divided by

(2) the sum of such tax and the price for which so sold;

(b) Noncompliance periods.—A day is described in this subsection with respect to a selected drug if it is a day during one of the following periods:

(1) The period beginning on the June 16th immediately following the selected drug publication date and ending on the first date during which the manufacturer of the drug has in place an agreement described in subsection (e) of section 1193 of the Social Security Act with respect to such drug;

(2) The period beginning on the April 1st immediately following the June 16th described in paragraph (1) and ending on the first date during which the manufacturer of the drug has agreed to a maximum fair price under such agreement;

(3) In the case of a selected drug with respect to which the Secretary of Health and Human Services has specified a renegotiation period under such agreement, the period beginning on the first date after the last date of such renegotiation period and ending on the first date during which the manufacturer of the drug has agreed to a renegotiated maximum fair price under such agreement;

(4) With respect to information that is required to be submitted to the Secretary of Health and Human Services under such agreement, the period beginning on the date on which such Secretary certifies that such information is overdue and ending on the date that such information is so submitted;

(5) In the case of a selected drug with respect to which a payment is due under subsection (c) of such section 1193, the period beginning on the date on which the Secretary of Health and Human Services certifies that such payment is overdue and ending on the date that such payment is made in full;

(c) Applicable percentage.—For purposes of this section, the term 'applicable percentage' means—

(1) in the case of sales of a selected drug during the first 90 days described in subsection (b) with respect to such drug, 65 percent;

(2) in the case of sales of such drug during the 91st day through the 180th day described in subsection (b) with respect to such drug, 75 percent;

(3) in the case of sales of such drug during the 181st day through the 270th day described in subsection (b) with respect to such drug, 85 percent; and

(4) in the case of sales of such drug during any subsequent day, 95 percent;

(d) Selected drug.—For purposes of this section—
"(4) IN GENERAL:— The term 'selected drug' means any selected drug (within the meaning of section 1192 of the Social Security Act) which is manufactured or produced in the United States or entered into the United States for consumption, use, or warehousing.

"(2) UNITED STATES.— The term 'United States' has the meaning given such term by section 4192(a)(4):

"(3) COORDINATION WITH RULES FOR POSSESSIONS OF THE UNITED STATES.— Rules similar to the rules of paragraphs (2) and (4) of section 4192(e) shall apply for purposes of this section:

"(e) OTHER DEFINITIONS.— For purposes of this section, the terms 'selected drug publication date' and 'maximum fair price' have the meaning given such terms in section 1191 of the Social Security Act:

"(f) ANTI-ABUSE RULE.— In the case of a sale which was timed for the purpose of avoiding the tax imposed by this section, the Secretary may treat such sale as occurring during a day described in subsection (b).".

(b) NO-DEDUCTION FOR EXCISE TAX PAYMENTS.— Section 275 of the Internal Revenue Code of 1986 is amended by adding "or by section 4192" before the period at the end of subsection (a)(6):

(c) CONFORMING AMENDMENTS.—

(1) Section 4221(a) of the Internal Revenue Code of 1986 is amended by inserting "or 4192" after "section 4194":

(2) Section 6416(b)(2) of such Code is amended by inserting "or 4192" after "section 4194":

(d) CLERICAL AMENDMENTS:—

(1) The heading of subchapter E of chapter 32 of the Internal Revenue Code of 1986 is amended by striking "Medical devices" and inserting "Other medical products";

(2) The table of subchapters for chapter 32 of such Code is amended by striking the item relating to subchapter E and inserting the following new item:

"SUBCHAPTER E: OTHER MEDICAL PRODUCTS":

(3) The table of sections for subchapter E of chapter 32 of such Code is amended by adding at the end the following new item:

"Sec. 4192: Selected drugs during noncompliance periods."

(e) EFFECTIVE DATE.— The amendments made by this section shall apply to sales after the date of the enactment of this Act:

Sec. 139093. Fair Price Negotiation Implementation Fund

(a) IN GENERAL.— There is hereby established a Fair Price Negotiation Implementation Fund (referred to in this section as the "Fund"). The Secretary of Health and Human Services
may obligate and expend amounts in the Fund to carry out this part and parts 2 and 3 (and the amendments made by such parts).

(b) FUNDING.—There is authorized to be appropriated, and there is hereby appropriated, out of any moneys in the Treasury not otherwise appropriated, to the Fund $3,000,000,000, to remain available until expended, of which—

(1) $600,000,000 shall become available on the date of the enactment of this Act;
(2) $600,000,000 shall become available on October 1, 2022;
(3) $600,000,000 shall become available on October 1, 2024;
(4) $600,000,000 shall become available on October 1, 2026; and
(5) $600,000,000 shall become available on October 1, 2026.

(c) SUPPLEMENT NOT SUPPLANT.—Any amounts appropriated pursuant to this section shall be in addition to any other amounts otherwise appropriated pursuant to any other provision of law.

Part 2—Prescription Drug Inflation Rebates

Sec. 139401. Medicare part B rebate by manufacturers

(a) IN GENERAL.—
Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by adding at the end the following new subsection:

"(e) REBATE BY MANUFACTURERS FOR SINGLE SOURCE DRUGS WITH PRICES INCREASING FASTER THAN INFLATION.—"

"(1) REQUIREMENTS.—"

"(A) SECRETARIAL PROVISION OF INFORMATION.—Not later than 6 months after the end of each calendar quarter beginning on or after July 1, 2023, the Secretary shall, for each part B rebateable drug, report to each manufacturer of such part B rebateable drug for such calendar quarter:

"(i) Information on the total number of units of the billing and payment code described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter.

"(ii) Information on the amount (if any) of the excess average sales-price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter.

"(iii) The rebate amount specified under such paragraph for such part B rebateable drug and calendar quarter.

(B) MANUFACTURER REQUIREMENT.—For each calendar quarter beginning on or after July 1, 2023, the manufacturer of a part B rebateable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter."
(2) PART B REBATABLE DRUG DEFINED.

(A) IN GENERAL.—In this subsection, the term "part B rebatable drug" means a single-source drug or biological (as defined in subparagraph (B) of section 1847A(e)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such section), payable (if such drug were furnished to an individual enrolled under this part) under this part, except such term shall not include such a drug or biological—

(i) if the average total allowed charges under this part as determined by the Secretary for a year per individual that uses such a drug or biological, as determined by the Secretary, are less than, subject to subparagraph (B), $100; or

(ii) that is a vaccine described in subparagraph (A) or (B) of section 1861(s)(10).

(B) INCREASE.—The dollar amount applied under subparagraph (A)(i)—

(i) for 2024, shall be the dollar amount specified under such subparagraph for 2023, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period ending with June of the previous year; and

(ii) for a subsequent year, shall be the dollar amount specified in this clause (or clause (i)) for the previous year, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period ending with June of the previous year.

Any dollar amount specified under this subparagraph that is not a multiple of $10 shall be rounded to the nearest multiple of $10.

(3) Rebate amount.—

(A) IN GENERAL.—For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraph (B) and paragraph (4), the amount equal to the product of—

(i) the total number of units, as described in section 1847A(e)(4)(B), with respect to such drug during the calendar quarter; and

(ii) the amount (if any) by which—

(I) the payment amount under subparagraph (B) or (C) of section 1847A(b)(1), as applicable, for such part B rebatable drug during the calendar quarter exceeds

(II) the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter.

(B) Excluded units.—For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units with respect to a part B rebatable drug during the calendar quarter units of such part B rebatable drug for which payment was
made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for the most recent rebate period.

"(C) DETERMINATION OF INFLATION-ADJUSTED PAYMENT AMOUNT.—The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is—

"(i) the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D)); increased by

"(ii) the percentage by which the rebate period CPI-U (as defined in subparagraph (F)) for the calendar quarter exceeds the benchmark period CPI-U (as defined in subparagraph (E));

"(D) PAYMENT AMOUNT BENCHMARK QUARTER.—The term ‘payment amount benchmark quarter’ means the calendar quarter beginning January 1, 2016.

"(E) BENCHMARK PERIOD CPI-U.—The term ‘benchmark period CPI-U’ means the consumer price index for all urban consumers (United States city average) for July 2014.

"(F) REBATE PERIOD CPI-U.—The term ‘rebate period CPI-U’ means, with respect to a calendar quarter described in subparagraph (C), the greater of the benchmark period CPI-U and the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter.

"(4) SPECIAL TREATMENT OF CERTAIN DRUGS AND EXEMPTIONS—

"(A) SUBSEQUENTLY APPROVED DRUGS.—Subject to subparagraph (B), in the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after July 1, 2015, clause (i) of paragraph (3)(C) shall be applied as if the term ‘payment amount benchmark quarter’ were defined under paragraph (3)(D) as the third full calendar quarter after the day on which the drug was first marketed and clause (ii) of paragraph (3)(C) shall be applied as if the term ‘benchmark period CPI-U’ were defined under paragraph (3)(E) as if the reference to ‘July 2015’ under such paragraph were a reference to ‘the first month of the first full calendar quarter after the day on which the drug was first marketed’.

"(B) TIMELINE FOR PROVISION OF REBATES FOR SUBSEQUENTLY APPROVED DRUGS.—In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after July 1, 2015, paragraph (1)(B) shall be applied as if the reference to ‘July 1, 2023’ under such paragraph were a reference to the later of the 6th full calendar quarter after the day on which the drug was first marketed or July 1, 2023.

"(C) EXEMPTION FOR SHORTAGES.—The Secretary may reduce or waive the rebate amount under paragraph (1)(B) with respect to a part B rebatable drug that is described as currently in shortage on the shortage list in effect under section 506E of the Federal Food, Drug, and Cosmetic Act or in the case of other exigent circumstances, as determined by the Secretary.
(D) SELECTED DRUGS.— In the case of a part B rebatable drug that is a selected drug (as defined in section 1102(c)) for a price applicability period (as defined in section 1191(b)(2))—

(ii) for calendar quarters during such period for which a maximum fair price (as defined in section 1191(c)(2)) for such drug has been determined and is applied under part E of title XI, the rebate amount under paragraph (1)(B) shall be waived; and

(ii) in the case such drug is determined (pursuant to such section 1192(c)) to no longer be a selected drug, for each applicable year beginning after the price applicability period with respect to such drug, clause (i) of paragraph (3)(C) shall be applied as if the term "payment amount benchmark quarter" were defined under paragraph (3)(D) as the calendar quarter beginning January 1 of the last year beginning during such price applicability period with respect to such selected drug and clause (ii) of paragraph (3)(C) shall be applied as if the term "benchmark period CPI-U" were defined under paragraph (3)(E) as if the reference to "July 2015" under such paragraph were a reference to the July of the year preceding such last year.

(E) APPLICATION TO BENEFICIARY-COINSURANCE.— In the case of a part B rebatable drug, if the payment amount under this part for a quarter exceeds the inflation-adjusted payment for such quarter—

(A) in computing the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished, the computation of such coinsurance shall be based on the inflation-adjusted payment amount determined under paragraph (3)(C) for such part B rebatable drug; and

(B) the amount of such coinsurance is equal to 20 percent of such inflation-adjusted payment amount so determined:

(F) REBATE DEPOSITS.— Amounts paid as rebates under paragraph (1)(B) shall be deposited into the Federal Supplementary Medical Insurance Trust Fund established under section 1844:

(G) CIVIL-MONEY PENALTY.— If a manufacturer of a part B rebatable drug has failed to comply with the requirements under paragraph (1)(B) for such drug for a calendar quarter, the manufacturer shall be subject to, in accordance with a process established by the Secretary pursuant to regulations, a civil-money penalty in an amount equal to at least 425 percent of the amount specified in paragraph (3) for such drug for such calendar quarter. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil-money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a):

(H) APPLICATION TO MULTIPLE SOURCE DRUGS.— The Secretary may, pursuant to rulemaking, apply the provisions of this subsection to multiple source drugs (as defined in section 1847A(c)(6)(C)), including for purposes of determining the rebate amount under
paragraph (3), by calculating manufacturer-specific average sales prices for the benchmark period and the rebate period.

(b) AMOUNTS PAYABLE; COST-SHARING.—Section 1833 of the Social Security Act (42 U.S.C. 1395j) is amended—

(1) in subsection (a)—

(A) in paragraph (1)—

(i) in subparagraph (G), by inserting "subject to subsection (i)(2)," after "the amounts paid;"

(ii) in subparagraph (J), by striking "with respect to" and inserting "subject to subparagraph (BD), with respect to;"

(iii) by striking "and (DD)" and inserting "and (EE)"; and

(iv) by inserting before the semicolon at the end the following: ", and (EE) with respect to a part B rebatable drug (as defined in paragraph (2) of section 1834(z)) for which the payment amount for a calendar quarter under paragraph (3)(A)(ii)(I) of such section for such quarter exceeds the inflation-adjusted payment under paragraph (3)(A)(ii)(II) of such section for such quarter, the amounts paid shall be the difference between (i) the payment amount under paragraph (3)(A)(ii)(I) of such section for such drug, and (ii) 20 percent of the inflation-adjusted payment amount under paragraph (3)(A)(ii)(II) of such section for such drug; and

(B) by adding at the end of the flush left matter following paragraph (9), the following: For purposes of applying paragraph (1)(EE), subsections (1)(B) and (1)(F) and section 1834(z)(5), the Secretary shall make such estimates and use such data as the Secretary determines appropriate, and may do so by program instruction or otherwise:

(2) in subsection (b), by adding at the end the following new paragraph:

"(9) In the case of a part B rebatable drug (as defined in paragraph (2) of section 1834(z)) for which payment under this subsection is not packaged into a payment for a covered OPD service (as defined in subsection (l)(1)(B)) (or group of services) furnished on or after July 1, 2023, under the system under this subsection, in lieu of calculation of coinsurance and the amount of payment otherwise applicable under this subsection, the provisions of section 1834(z)(6), paragraph (1)(EE) of subsection (a) and the flush left matter following paragraph (9) of subsection (a), shall, as determined appropriate by the Secretary, apply under this subsection in the same manner as such provisions of section 1834(z)(6) and subsection (a) apply under such section and subsection, and

(3) in subsection (t)(6), by adding at the end the following new subparagraph:

"(F) PART B REBATABLE DRUGS.—In the case of a part B rebatable drug (as defined in paragraph (2) of section 1834(z)) for which payment under this part is not packaged into a payment for service furnished on or after July 1, 2023, under the system under this subsection, in lieu of calculation of coinsurance and the amount of
payment—otherwise applicable under this subsection, the provisions of section 4834(z)(5); paragraph (1)(EE) of subsection (a); and the flush-left matter following paragraph (9) of subsection (a); shall, as determined appropriate by the Secretary, apply under this subsection in the same manner as such provisions of section 4834(z)(5) and subsection (a) apply under such section and subsection.".

(e) CONFORMING AMENDMENTS.—

(1) To PART B ASP CALCULATION.—Section 1847A(e)(3) of the Social Security Act (42 U.S.C. 1395w–3(e)(3)) is amended by inserting "or section 1834(z)" after "section 4927".

(2) EXCLUDING PARTS B DRUG INFLATION REBATE FROM BEST PRICE.—Section 4927(e)(1)(C)(ii)(I) of the Social Security Act (42 U.S.C. 1395w–8(e)(1)(C)(ii)(I)) is amended by inserting "or section 1834(z)" after "this section".

(3) COORDINATION WITH MEDICAID REBATE INFORMATION DISCLOSURE.—Section 4927(b)(3)(D)(II) of the Social Security Act (42 U.S.C. 1395w–8(b)(3)(D)(II)) is amended by striking "or to carry out section 1847B" and inserting "or section 1834(z)".

Sec. 139102. Medicare part D rebate by manufacturers

(a) IN GENERAL.—

Part D of title XVIII of the Social Security Act is amended by inserting after section 1869D–144A (42 U.S.C. 1395w–144a) the following new section:

"Sec. 1869D–14B. Manufacturer rebate for certain drugs with prices increasing faster than inflation

"(a) REQUIREMENTS.—

(1) SECRETARIAL PROVISION OF INFORMATION.—Not later than 9 months after the end of each applicable year (as defined in subsection (g)(7)), the Secretary shall, for each part D rebatable drug, report to each manufacturer of such part D rebatable drug the following for such year:

(A) Information on the amount (if any) of the excess average manufacturer price increase described in subsection (b)(1)(B) for each dosage form and strength with respect to such drug and year;

(B) The rebate amount specified under subsection (b) for each dosage form and strength with respect to such drug and year;

(2) MANUFACTURER REQUIREMENTS.—For each applicable year, the manufacturer of a part D rebatable drug, for each dosage form and strength with respect to such drug, not later than 30 days after the date of receipt from the Secretary of the information described in paragraph (1) for such year, shall provide to the Secretary a rebate that is equal to the amount specified in subsection (b) for such dosage form and strength with respect to such drug for such year.

(b) PAYMENT AMOUNT—

(1) GENERAL—

(2)
"(A) C A L C U L A T I O N. — For purposes of this section, the amount specified in this subsection for a dosage form and strength with respect to a part D rebateable drug and applicable year is— subject to subparagraph (B) of this paragraph and subparagraphs (B) and (C) of paragraph (5), the amount equal to the product of—

"(i) the total number of units that are used to calculate the average manufacturer price of such dosage form and strength with respect to such part D rebateable drug, as reported by the manufacturer of such drug under section 1927 for each recent rebate period under such section, with respect to such year, under such section for which such information is available; and

"(ii) the amount (if any) by which—

"(I) the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebateable drug for the year exceeds

"(II) the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebateable drug for the year.

"(B) E X C L U S E D U N I T S. — For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebateable drug and the most recent rebate period under section 1927, with respect to an applicable year, for which such information is available, units of each dosage form and strength of such part D rebateable drug, for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for such rebate period.

"(2) D E T E R M I N A T I O N O F A N N U A L M A N U F A C T U R E R P R I C E. — The annual manufacturer price determined under this paragraph for a dosage form and strength, with respect to a part D rebateable drug and an applicable year, is the sum of the products of—

"(A) the average manufacturer price (as defined in subsection (g)(6)) of such dosage form and strength, as calculated for a unit of such drug, with respect to each of the calendar quarters of such year; and

"(B) the ratio of—

"(i) the total number of units of such dosage form and strength reported for the purpose of calculating average manufacturer price under section 1927 during each such calendar quarter of such year; to

"(ii) the total number of units of such dosage form and strength reported for the purpose of calculating average manufacturer price under section 1927 during such year, as determined by the Secretary.

"(3) D E T E R M I N A T I O N O F I N F L A T I O N - A D J U S T E D P A Y M E N T A M O U N T. — The inflation-adjusted payment amount determined under this paragraph for a dosage form and strength with respect to a part D rebateable drug for an applicable year, subject to subparagraphs (A) and (B) of paragraph (5), is—
"(A) the benchmark year manufacturer price determined under paragraph (4) for such dosage form and strength with respect to such drug and year, increased by
"(B) the percentage by which the applicable year CPI-U (as defined in subsection (g)(3)) for the year exceeds the benchmark period CPI-U (as defined in subsection (g)(4));
"(4) DETERMINATION OF BENCHMARK YEAR MANUFACTURER PRICE.— The benchmark year manufacturer price determined under this paragraph for a dosage form and strength, with respect to a part D rebatable drug and an applicable year, is the sum of the products of
"(A) the average manufacturer price (as defined in subsection (g)(6)) of such dosage form and strength, as calculated for a unit of such drug, with respect to each of the calendar quarters of the payment amount benchmark year (as defined in subsection (g)(3)); and
"(B) the ratio of
"(i) the total number of units of such dosage form and strength dispensed during each such calendar quarter of such payment amount benchmark year; to
"(ii) the total number of units of such dosage form and strength dispensed during such payment amount benchmark year;
"(5) SPECIAL TREATMENT OF CERTAIN DRUGS AND EXEMPTION:—
"(A) SUBSEQUENTLY APPROVED DRUGS.— In the case of a part D rebatable drug first approved or licensed by the Food and Drug Administration after January 1, 2016, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term 'payment amount benchmark year' were defined under subsection (g)(3) as the first calendar year beginning after the day on which the drug was first marketed by any manufacturer and subparagraph (B) of paragraph (3) shall be applied as if the term 'benchmark period CPI-U' were defined under subsection (g)(4) as if the reference to 'January 2016' under such subsection were a reference to 'January of the first year beginning after the date on which the drug was first marketed by any manufacturer';
"(B) EXEMPTION FOR SHORTAGES.— The Secretary may reduce or waive the rebate under paragraph (1) with respect to a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 506E of the Federal Food, Drug, and Cosmetic Act or in the case of other exigent circumstances, as determined by the Secretary;
"(C) TREATMENT OF NEW FORMULATIONS:—
"(i) IN GENERAL.— In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the amount specified in this subsection with respect to such part D rebatable drug and an applicable year with consideration of the original part D rebatable drug;
"(ii) LINE EXTENSIONS—DEFINED.— In this subparagraph, the term 'line extension' means, with respect to a part D rebatable drug, a new formulation of
the drug, such as an extended-release formulation, but does not include an abuse-deterrent formulation of the drug (as determined by the Secretary); regardless of whether such abuse-deterrent formulation is an extended-release formulation:

"(D) SELECTED DRUGS.—In the case of a part D rebateable drug that is a selected drug (as defined in section 1192(e)) for a price applicability period (as defined in section 1191(b)(2))—

"(i) for plan years during such period for which a maximum fair price (as defined in section 1194(e)(2)) for such drug has been determined and is applied under part E of title XI, the rebate under subsection (e)(1)(B) shall be waived; and

"(ii) in the case such drug is determined (pursuant to such section 1192(e)) to no longer be a selected drug, for each applicable year beginning after the price applicability period with respect to such drug, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term ‘payment amount benchmark year’ were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph (B) of paragraph (3) shall be applied as if the term ‘benchmark period CPI-U’ were defined under subsection (g)(4) as if the reference to January 2016 under such subsection were a reference to January of the last year beginning during such price applicability period with respect to such drug;

"(e) REBATE DEPOSITS.—Amounts paid as rebates under subsection (b) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1441:

"(d) INFORMATION.—For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A);

"(e) CIVIL MONEY PENALTY.—If a manufacturer of a part D rebateable drug has failed to comply with the requirement under subsection (a)(1)(B) with respect to such drug for an applicable year, the manufacturer shall be subject to, in accordance with a process established by the Secretary pursuant to regulations, a civil money penalty in an amount equal to 125 percent of the amount specified in subsection (b) for such drug for such year. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 4128A(a):

"(f) JUDICIAL REVIEW.—There shall be no judicial review of the following:

"(4) The determination of units under this section;

"(2) The determination of whether a drug is a part D rebateable drug under this section;

"(3) The calculation of the rebate amount under this section;

"(g) DEFINITIONS.—In this section:
"(4) Part D rebateable drug defined.—

"(A) In general. — The term "part D rebateable drug" means a drug or biological that would (without application of this section) be a covered part D drug, except such term shall, with respect to an applicable year, not include such a drug or biological if the average annual total cost under this part for such year per individual who uses such a drug or biological, as determined by the Secretary, is less than subject to subparagraph (B), $100, as determined by the Secretary using the most recent data available or, if data is not available, as estimated by the Secretary.

"(B) Increase. — The dollar amount applied under subparagraph (A)—

"(i) for 2024, shall be the dollar amount specified under such subparagraph for 2023, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with January of 2023; and

"(ii) for a subsequent year, shall be the dollar amount specified in this subparagraph for the previous year, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with January of the previous year.

Any dollar amount specified under this subparagraph that is not a multiple of $10 shall be rounded to the nearest multiple of $10.

"(2) Unit defined.— The term "unit" means, with respect to a part D rebateable drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebateable drug, including data reported under section 1927.

"(3) Payment amount benchmark year.— The term "payment amount benchmark year" means the year beginning January 1, 2016.

"(4) Benchmark period CPI-U.— The term "benchmark period CPI-U" means the consumer price index for all urban consumers (United States city average) for January 2016.

"(5) Applicable year CPI-U.— The term "applicable year CPI-U" means, with respect to an applicable year, the consumer price index for all urban consumers (United States city average) for January of such year.

"(6) Average manufacturer price.— The term "average manufacturer price" has the meaning, with respect to a part D rebateable drug of a manufacturer, given such term in section 1927(h)(4), with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1927.

"(7) Applicable year.— The term "applicable year" means a year beginning with 2023."

(b) Conforming amendments.—

(1) To part D ASP calculation.—Section 1847A(e)(3) of the Social Security Act (42 U.S.C. 1395w-3(a)(e)(3)), as amended by section 139101(e)(1), is further amended by striking "section 1927 or section 4034(z)" and inserting "section 1927, section 1834(t), or section 1860B-14B";
(2) Excluding Part D Drug Inflation Rebate from Best Price.—Section 1927(e)(1)(B)(i)(I) of the Social Security Act (42 U.S.C. 1396r-8(e)(1)(C)(ii)(I)), as amended by section 139101(e)(2), is further amended by striking "or section 1834(z)" and inserting "section 1834(z), or section 1860D-14B".

(3) Coordination with Medicaid Rebate Information Disclosure.—Section 1927(b)(3)(D)(i) of the Social Security Act (42 U.S.C. 1396r-8(b)(3)(D)(i)), as amended by section 139101(e)(3), is further amended by striking "or section 1834(z)" and inserting "section 1834(z), or section 1860D-14B".

Part 3—Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries

Sec. 139201. Medicare Part D benefit redesign

(a) Benefit structure redesign.—Section 1860D-2(b) of the Social Security Act (42 U.S.C. 1395w–102(b)) is amended—

(1) in paragraph (2)—

(A) in subparagraph (A), in the matter preceding clause (i), by inserting "for a year preceding 2024 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4) for 2024 and each subsequent year" after "paragraph (3)";

(B) in subparagraph (C)—

(i) in clause (i), in the matter preceding subclause (I), by inserting "for a year preceding 2024, "after "paragraph (4)"; and

(ii) in clause (ii)(III), by striking "and each subsequent year" and inserting "through 2023"; and

(C) in subparagraph (D)—

(i) in clause (i)—

(I) in the matter preceding subclause (I), by inserting "for a year preceding 2024, "after "paragraph (4)"; and

(II) in subclause (I)(bb), by striking "a year after 2019" and inserting "each of years 2018 through 2023"; and

(ii) in clause (ii)(V), by striking "2019 and each subsequent year" and inserting "each of years 2019 through 2023";

(2) in paragraph (3)(A)—

(A) in the matter preceding clause (i), by inserting "for a year preceding 2024," after "and (4);" and

(B) in clause (ii), by striking "for a subsequent year" and inserting "for each of years 2007 through 2023;" and

(3) in paragraph (4)—

(A) in subparagraph (A)—
(i) in clause (i)—

(i) by redesignating subclauses (i) and (ii) as items (aa) and (bb), respectively; and moving the margin of each such redesignated item 2 spaces to the right;

(II) in the matter preceding item (aa), as redesignated by subclause (i), by striking "is equal to the greater of—" and inserting "is equal to—"

"(i) for a year preceding 2024, the greater of—";

(III) by striking the period at the end of item (bb), as redesignated by subclause (i), and inserting "; and"; and

(IV) by adding at the end the following:

"(ii) for 2024 and each succeeding year, $0;" and

(ii) in clause (ii), by striking "clause (i)(i)" and inserting "clause (i)(i)(aa)";

(B) in subparagraph (B)—

(i) in clause (i)—

(i) in subclause (V), by striking "or" at the end;

(II) in subclause (VI)—

(aa) by striking "for a subsequent year" and inserting "for each of years 2021 through 2023;" and

(bb) by striking the period at the end and inserting a semicolon;

and

(III) by adding at the end the following new subclauses:

"(VII) for 2024, is equal to $2,000; or

"(VIII) for a subsequent year, is equal to the amount specified in this subparagraph for the previous year, increased by the annual percentage increase described in paragraph (F) for the year involved.";

and

(ii) in clause (ii), by striking "clause (i)(II)" and inserting "clause (i)";

(C) in subparagraph (C)(i), by striking "and for amounts" and inserting "and, for a year preceding 2024, for amounts;" and

(D) in subparagraph (E), by striking "in applying" and inserting "For each of years 2011 through 2023, in applying".

(b) DECREASING REINSURANCE PAYMENT AMOUNT.—Section 1860D–15(b)(4) of the Social Security Act (42 U.S.C. 1395w–116(b)(4)) is amended by inserting after "80 percent" the following: "(or, with respect to a coverage year after 2023, 20 percent)"

(c) MANUFACTURER DISCOUNT PROGRAM.—

(†) IN GENERAL.—Part D of title XVIII of the Social Security Act (42 U.S.C. 1395w–401 et seq.), as amended by section 139402, is further amended by inserting after section 139402 the following new section:

"Sec. 1860D–14G. Manufacturer discount program
"(a) ESTABLISHMENT.—The Secretary shall establish a manufacturer-discount program (in this section referred to as the ‘program’). Under the program, the Secretary shall enter into agreements described in subsection (b) with manufacturers and provide for the performance of the duties described in subsection (c). The Secretary shall establish a model agreement for use under the program by not later than January 1, 2023, in consultation with manufacturers, and allow for comment on such model agreement.

"(b) TERMS OF AGREEMENT.—

"(1) IN GENERAL.—

"(A) AGREEMENT.—An agreement under this section shall require the manufacturer to provide applicable beneficiaries access to discounted prices for applicable drugs of the manufacturer that are dispensed on or after January 1, 2024.

"(B) PROVISION OF DISCOUNTED PRICES AT THE POINT OF SALE.—The discounted prices described in subparagraph (A) shall be provided to the applicable beneficiary at the pharmacy or by the mail order service at the point of sale of an applicable drug.

"(C) TIMING OF AGREEMENT.—

"(i) SPECIAL RULE FOR 2024.—In order for an agreement with a manufacturer to be in effect under this section with respect to the period beginning on January 1, 2024, and ending on December 31, 2024, the manufacturer shall enter into such agreement not later than 30 days after the date of the establishment of a model agreement under subsection (a).

"(ii) 2025 AND SUBSEQUENT YEARS.—In order for an agreement with a manufacturer to be in effect under this section with respect to plan year 2025 or a subsequent plan year, the manufacturer shall enter into such agreement (or such agreement shall be renewed under paragraph (4)(A)) not later than January 30 of the preceding year.

"(2) PROVISION OF APPROPRIATE DATA.—Each manufacturer with an agreement in effect under this section shall collect and have available appropriate data, as determined by the Secretary, to ensure that it can demonstrate to the Secretary compliance with the requirements under the program.

"(3) COMPLIANCE WITH REQUIREMENTS FOR ADMINISTRATION OF PROGRAM.—Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under subsection (d)(3), as applicable, for purposes of administering the program, including any determination under subparagraph (A) of subsection (c)(1) and procedures established under such subsection (c)(1).

"(4) LENGTH OF AGREEMENT.—

"(A) IN GENERAL.—An agreement under this section shall be effective for an initial period of not less than 12 months and shall be automatically renewed for a period of not less than 1 year unless terminated under subparagraph (B):
"(B) TERMINATION:—

(i) By the Secretary.—The Secretary may provide for termination of an agreement under this section for a knowing and willful violation of the requirements of the agreement or other good cause shown. Such termination shall not be effective earlier than 30 days after the date of notice to the manufacturer of such termination. The Secretary shall provide, upon request, a manufacturer with a hearing concerning such a termination, and such hearing shall take place prior to the effective date of the termination with sufficient time for such effective date to be repealed if the Secretary determines appropriate.

(ii) By a manufacturer.—A manufacturer may terminate an agreement under this section for any reason. Any such termination shall be effective, with respect to a plan year—

(i) if the termination occurs before January 30 of a plan year, as of the day after the end of the plan year; and

(ii) if the termination occurs on or after January 30 of a plan year, as of the day after the end of the succeeding plan year.

(iii) Effectiveness of termination.—Any termination under this subparagraph shall not affect discounts for applicable drugs of the manufacturer that are due under the agreement before the effective date of its termination.

(iv) Notice to third party.—The Secretary shall provide notice of such termination to a third party with a contract under subsection (d)(3) within not less than 30 days before the effective date of such termination.

(c) Duties described.—The duties described in this subsection are the following:

(1) Administration of program.—Administering the program, including—

(A) the determination of the amount of the discounted price of an applicable drug of a manufacturer;

(B) the establishment of procedures under which discounted prices are provided to applicable beneficiaries at pharmacies or by mail order service at the point of sale of an applicable drug;

(C) the establishment of procedures to ensure that, not later than the applicable number of calendar days after the dispensing of an applicable drug by a pharmacy or mail order service, the pharmacy or mail order service is reimbursed for an amount equal to the difference between—

(i) the negotiated price of the applicable drug; and

(ii) the discounted price of the applicable drug;

(D) the establishment of procedures to ensure that the discounted price for an applicable drug under this section is applied before any coverage or financial assistance under other health benefit plans or programs that provide coverage
or financial assistance for the purchase or provision of prescription drug coverage on behalf of applicable beneficiaries as the Secretary may specify; and

"(E) providing a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, applicable beneficiaries, and the third party with a contract under subsection (d)(3);

"(2) MONITORING COMPLIANCE:—

"(A) In general.—The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under this section.

"(B) Notification.—If a third party with a contract under subsection (d)(3) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such noncompliance for appropriate enforcement under subsection (e);

"(3) COLLECTION OF DATA FROM PRESCRIPTION DRUG PLANS AND MA–PD PLANS:—The Secretary may collect appropriate data from prescription drug plans and MA–PD plans in a timeframe that allows for discounted prices to be provided for applicable drugs under this section;

"(d) ADMINISTRATION:—

"(1) IN GENERAL.—Subject to paragraph (2), the Secretary shall provide for the implementation of this section, including the performance of the duties described in subsection (e):

"(2) LIMITATION.—In providing for the implementation of this section, the Secretary shall not receive or distribute any funds of a manufacturer under the program;

"(3) CONTRACT WITH THIRD PARTIES.—The Secretary shall enter into a contract with 1 or more third parties to administer the requirements established by the Secretary in order to carry out this section. At a minimum, the contract with a third party under the preceding sentence shall require that the third party—

"(A) receive and transmit information between the Secretary, manufacturers, and other individuals or entities the Secretary determines appropriate;

"(B) receive, distribute, or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to meet the obligations of manufacturers under agreements under this section;

"(C) provide adequate and timely information to manufacturers, consistent with the agreement with the manufacturer under this section, as necessary for the manufacturer to fulfill its obligations under this section; and

"(D) permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program;

"(4) PERFORMANCE REQUIREMENTS.—The Secretary shall establish performance requirements for a third party with a contract under paragraph (3) and
safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this section:

"(5) IMPLEMENTATION.—The Secretary may implement the program under this section by program instruction or otherwise:

"(6) ADMINISTRATION.—Chapter 35 of title 44, United States Code, shall not apply to the program under this section:

"(e) ENFORCEMENT—

"(1) AUDITS.—Each manufacturer with an agreement in effect under this section shall be subject to periodic audit by the Secretary:

"(2) CIVIL MONEY PENALTY.—

"(A) IN GENERAL.—The Secretary may impose a civil money penalty on a manufacturer that fails to provide applicable beneficiaries discounts for applicable drugs of the manufacturer in accordance with such agreement for each such failure in an amount the Secretary determines is equal to the sum of

"(i) the amount that the manufacturer would have paid with respect to such discounts under the agreement, which will then be used to pay the discounts which the manufacturer had failed to provide, and

"(ii) 25 percent of such amount:

"(B) APPLICATION.—The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a):

"(f) CLARIFICATION REGARDING AVAILABILITY OF OTHER COVERED PART D DRUGS.—Nothing in this section shall prevent an applicable beneficiary from purchasing a covered Part D drug that is not an applicable drug (including a generic drug or a drug that is not on the formulary of the prescription drug plan or MA-PD plan that the applicable beneficiary is enrolled in):

"(g) DEFINITIONS.—In this section:

"(1) APPLICABLE BENEFICIARY.—The term ‘applicable beneficiary’ means an individual who, on the date of dispensing a covered Part D drug—

"(A) is enrolled in a prescription drug plan or an MA-PD plan;

"(B) is not enrolled in a qualified retiree prescription drug plan; and

"(C) has incurred costs, as determined in accordance with section 1860D-2(b)(4)(C), for covered Part D drugs in the year that exceed the annual deductible with respect to such individual for such year, as specified in section 1860D-2(b)(1), section 1860D-14(a)(1)(B), or section 1860D-14(a)(2)(B), as applicable:

"(2) APPLICABLE DRUG.—The term ‘applicable drug’, with respect to an applicable beneficiary—
"(A) means a covered Part D drug—

(i) approved under a new drug application under section 505(c) of the Federal Food, Drug, and Cosmetic Act or, in the case of a biologic product, licensed under section 351 of the Public Health Service Act; and

(ii)

(ii)(f) if the PDP sponsor—or the MA organization offering the MA-PD plan—uses a formulary, which is on the formulary of the prescription drug plan or MA-PD plan that the applicable beneficiary is enrolled in;

(ii)(ii) if the PDP sponsor—or the MA organization offering the MA-PD plan—does not use a formulary, for which benefits are available under the prescription drug plan or MA-PD plan that the applicable beneficiary is enrolled in; or

(ii)(iii) is provided through an exception or appeal; and

(B) does not include a selected drug (as defined in section 1192(c)) during a price applicability period (as defined in section 1191(b)(2)) with respect to such drug:

(3) APPLICABLE NUMBER OF CALENDAR DAYS.—The term ‘applicable number of calendar days’ means—

(A) with respect to claims for reimbursement submitted electronically, 44 days; and

(B) with respect to claims for reimbursement submitted otherwise, 30 days.

(4) DISCOUNTED PRICE.—

(A) IN GENERAL.—The term ‘discounted price’ means, with respect to an applicable drug of a manufacturer dispensed during a year to an applicable beneficiary—

(i) who has not incurred costs, as determined in accordance with section 1860D-2(b)(4)(G), for covered Part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D-2(b)(4)(B)(i) for the year, 90 percent of the negotiated price of such drug; and

(ii) who has incurred such costs, as so determined, in the year that are equal to or exceed such threshold for the year, 70 percent of the negotiated price of such drug.

(B) CLARIFICATION.—Nothing in this section shall be construed as affecting the responsibility of an applicable beneficiary for payment of a dispensing fee for an applicable drug.

(C) SPECIAL CASE FOR CERTAIN CLAIMS.—

(i) CLAIMS SPANNING DEDUCTIBLE.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall above the annual
deductible specified in section 1860D–2(b)(1) for the year, the manufacturer of the applicable drug shall provide the discounted price under this section on only the portion of the negotiated price of the applicable drug that falls above such annual deductible:

"(ii) CLAIMS SPANNING OUT-OF-POCKET THRESHOLD.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall entirely below or entirely above the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the manufacturer of the applicable drug shall provide the discounted price—

"(i) in accordance with subparagraph (A)(i) on the portion of the negotiated price of the applicable drug that falls below such threshold; and

"(ii) in accordance with subparagraph (A)(ii) on the portion of such price of such drug that falls at or above such threshold:

"(5) MANUFACTURER.—The term ‘manufacturer’ means any entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of prescription drug products, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis. Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law.

"(6) NEGOTIATED PRICE.—The term ‘negotiated price’ has the meaning given such term in section 423.100 of title 42, Code of Federal Regulations (or any successor regulation), except that, with respect to an applicable drug, such negotiated price shall not include any dispensing fee for the applicable drug.

"(7) QUALIFIED RETIREE PRESCRIPTION DRUG PLAN.—The term ‘qualified retiree prescription drug plan’ has the meaning given such term in section 1860D–22(a)(2)."

(2) SUNSET OF MEDICARE COVERAGE GAP DISCOUNT PROGRAM.—Section 1860D–44A of the Social Security Act (42 U.S.C. 1395–1144a) is amended—

(A) in subsection (a), in the first sentence, by striking "The Secretary" and inserting "Subject to subsection (h), the Secretary"; and

(B) by adding at the end the following new subsection:

"(h) SUNSET OF PROGRAM.—

"(1) IN GENERAL.—The program shall not apply with respect to applicable drugs dispensed on or after January 1, 2024, and, subject to paragraph (2), agreements under this section shall be terminated as of such date.

"(2) CONTINUED APPLICATION FOR APPLICABLE DRUGS DISPENSED PRIOR TO SUNSET.—The provisions of this section (including all responsibilities and duties) shall continue to apply after January 1, 2024, with respect to applicable drugs dispensed prior to such date."
(3) INCLUSION OF ACTUARIAL VALUE OF MANUFACTURER DISCOUNTS IN BIDS.—Section 1860D-21 of the Social Security Act (42 U.S.C. 1395w-111) is amended—
(A) in subsection (b)(2)(C)(iii)—
   (i) by striking "assumptions regarding the reinsurance" and inserting "assumptions regarding—"
   "(i) the reinsurance"; and
   (ii) by adding at the end the following:
   "(ii)(I) for the year preceding 2024, the manufacturer discounts provided under section 1860D-14C after subtracting from the actuarial value to produce such bid; and"
and
(B) in subsection (c)(1)(C)—
   (i) by striking "an actuarial valuation of the reinsurance" and inserting "an actuarial valuation of—"
   "(i) the reinsurance";
   (ii) in clause (i), as inserted by clause (i) of this subparagraph, by adding "and" at the end; and
   (iii) by adding at the end the following:
   "(ii)(I) for the year preceding 2024, the manufacturer discounts provided under section 1860D-14C;"

(d) CONFORMING AMENDMENTS.—
(1) Section 1860D-2 of the Social Security Act (42 U.S.C. 1395w-102) is amended—
   (A) in subsection (a)(2)(A)(ii)(I), by striking "or an increase in the initial" and inserting "or, for a year preceding 2024, an increase in the initial";
   (B) in subsection (c)(1)(C)—
      (i) in the subparagraph heading, by striking "at initial coverage limit";
      (ii) by inserting "for a year preceding 2024 or the annual out-of-pocket threshold specified in subsection (b)(4)(B) for the year for 2024 and each subsequent year" after "subsection (b)(3) for the year" each place it appears; and
   (C) in subsection (d)(1)(A), by striking "or an initial" and inserting "or, for a year preceding 2024, an initial";
(2) Section 1860D-4(a)(4)(B)(i) of the Social Security Act (42 U.S.C. 1395w-104(a) (4)(B)(i)) is amended by striking "the initial" and inserting "for a year preceding 2024, the initial";
(3) Section 1860D-14(a) of the Social Security Act (42 U.S.C. 1395w-114(a)) is amended—
   (A) in paragraph (1)—
(i) in subparagraph (C), by striking "The continuation" and inserting "For a year preceding 2024, the continuation";
(ii) in subparagraph (D)(iii), by striking "1860D–2(b)(4)(A)(ii)(I)" and inserting "1860D–2(b)(4)(A)(i)(I)(ee)"; and
(iii) in subparagraph (E), by striking "The elimination" and inserting "For a year preceding 2024, the elimination"; and
(B) in paragraph (2)—
(i) in subparagraph (C), by striking "The continuation" and inserting "For a year preceding 2024, the continuation"; and
(A) by striking "the value of any discount" and inserting the following:
the value of—
"(i) for years prior to 2024, any discount";
(B) in clause (i), as inserted by subparagraph (A) of this paragraph, by striking the period at the end and inserting "; and"; and
(C) by adding at the end the following new clause:
"(ii) for 2024 and each subsequent year, any discount provided pursuant to section 1860D–14G;".
(6) Section 1860D–41(a)(6) of the Social Security Act (42 U.S.C. 1395w–151(a)(6)) is amended—
(A) by inserting "for a year before 2024" after "1860D–2(b)(3)"; and
(B) by inserting "for such year" before the period;
(7) Section 1860D–43 of the Social Security Act (42 U.S.C. 1395w–152) is amended—
(A) in subsection (a)—
(i) by striking paragraph (1) and inserting the following:
"(1) participate in—
"(A) for 2011 through 2023, the Medicare coverage gap discount program under section 1860D–14A; and
"(B) for 2024 and each subsequent year, the manufacturer discount program under section 1860D–14G;"
(ii) by striking paragraph (2) and inserting the following:
"(2) have entered into and have in effect—
"(A) for 2011 through 2023, an agreement described in subsection (b) of section 1860D-14A with the Secretary; and

"(B) for 2024 and each subsequent year, an agreement described in subsection (b) of section 1860D-14C with the Secretary; and"

(iii) by striking paragraph (3) and inserting the following:

"(3) have entered into and have in effect, under terms and conditions specified by the Secretary—

"(A) for 2011 through 2023, a contract with a third-party that the Secretary has entered into a contract with under subsection (d)(3) of section 1860D-14A; and

"(B) for 2024 and each subsequent year, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of section 1860D-14C."; and

(B) by striking subsection (b) and inserting the following:

"(b) EFFECTIVE DATE.— Paragraphs (1)(A), (2)(A), and (3)(A) of subsection (e) shall apply to covered Part D drugs dispensed under this part on or after January 1, 2011, and before January 1, 2024, and paragraphs (1)(B), (2)(B), and (3)(B) of such subsection shall apply to covered Part D drugs dispensed under this part on or after January 1, 2024.".

(b) Section 1927 of the Social Security Act (42 U.S.C. 1395w-102) is amended—

(A) in subsection (c)(1)(C)(i)(VI), by inserting before the period at the end the following: "or under the manufacturer-discount program under section 1860D-14C;

and

(B) in subsection (k)(4)(B)(i)(V), by inserting before the period at the end the following: "or under section 1860D-14C,.

(e) EFFECTIVE DATE.—The amendments made by this section shall apply with respect to plan year 2024 and subsequent plan years.

Sec. 139202. Allowing certain enrollees of prescription-drug plans and MA-PD plans under Medicare program to spread out cost-sharing under certain circumstances

Section 1880D-2(b)(2) of the Social Security Act (42 U.S.C. 1395w-102(b)(2)), as amended by section 139201, is further amended—

(1) in subparagraph (A), by striking "Subject to subparagraphs (C) and (D)" and inserting "Subject to subparagraphs (C), (D), and (E)"; and

(2) by adding at the end the following new subparagraph:

"(E) ENROLLEE OPTION REGARDING SPREADING COST-SHARING.—The Secretary shall establish by regulation a process under which, with respect to plan year 2024 and subsequent plan years, a prescription drug plan or an MA-PD plan shall, in the case of a Part D-eligible individual enrolled with such plan for such plan year who is not a subsidy-eligible individual (as defined in section 1860D-14(a)(3)) and with respect to whom the plan projects that the dispensing of the first fill of a covered part
D drug to such individual will result in the individual incurring costs that are equal to or above the annual out-of-pocket-threshold specified in paragraph (4)(B) for such plan year, provide such individual with the option to make the coinsurance payment required under subparagraph (A) (for the portion of such costs that are not above such annual out-of-pocket-threshold) in the form of periodic installments over the remainder of such plan year."

Part 4—Repeal of Certain Prescription Drug Rebate Rule

Sec. 439301. Prohibiting implementation of rule relating to eliminating the anti-kickback statute safe harbor protection for prescription drug rebates

Beginning January 1, 2026, the Secretary of Health and Human Services shall not implement, administer, or enforce the provisions of the final rule published by the Office of the Inspector General of the Department of Health and Human Services on November 30, 2020, and titled "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-Of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees" (85 Fed. Reg. 76666);

* Sec. 439001. Providing for lower prices for certain high-priced single source drugs

(a) Program to lower prices for certain high-priced single source drugs—Title XI of the Social Security Act (42 U.S.C. 1391 et seq.) is amended by adding at the end the following new part:

"Part E—Fair Price Negotiation Program to Lower Prices for Certain High-Priced Single-Source Drugs

"Sec. 4191. Establishment of program

(a) IN GENERAL.—The Secretary shall establish a Fair Price Negotiation Program (in this part referred to as the "program"). Under the program, with respect to each price-applicability period, the Secretary shall—

1. publish a list of selected drugs in accordance with section 1192;
2. enter into agreements with manufacturers of selected drugs with respect to such period, in accordance with section 1193;
3. negotiate and, if applicable, renegotiate maximum fair prices for such selected drugs, in accordance with section 1194; and
4. carry out the administrative duties described in section 1196;

(b) Definitions relating to timing.—For purposes of this part:

1. Initial price-applicability year.—The term "initial price-applicability year" means a plan year (beginning with plan year 2025) or, if agreed to in an agreement under section 1193 by the Secretary and manufacturer involved, a period of more than one plan year (beginning on or after January 1, 2025)."
"(2) Price applicability period.—The term "price applicability period" means, with respect to a drug, the period beginning with the initial price applicability year with respect to which such drug is a selected drug and ending with the last plan year during which the drug is a selected drug.

"(3) Selected drug publication date.—The term "selected drug publication date" means, with respect to each initial price applicability year, April 15 of the plan year that begins 2 years prior to such year.

"(4) Voluntary negotiation period.—The term "voluntary negotiation period" means, with respect to an initial price applicability year with respect to a selected drug, the period—

"(A) beginning on the sooner of—

"(i) the date on which the manufacturer of the drug and the Secretary enter into an agreement under section 1193 with respect to such drug; or

"(ii) June 15 following the selected drug publication date with respect to such selected drug; and

"(B) ending on March 31 of the year that begins one year prior to the initial price applicability year.

"(e) Other definitions.—For purposes of this part:

"(4) Fair price eligible individual.—The term "fair price eligible individual" means, with respect to a selected drug—

"(A) in the case such drug is furnished or dispensed to the individual at a pharmacy or by a mail order service—

"(i) an individual who is enrolled under a prescription drug plan under part D of title XVIII or an MA-PD plan under part C of such title if coverage is provided under such plan for such selected drug; and

"(ii) an individual who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or dispensed; and

"(B) in the case such drug is furnished or administered to the individual by a hospital, physician, or other provider of services or supplier—

"(i) an individual who is entitled to benefits under part A of title XVIII or enrolled under part B of such title if such selected drug is covered under the respective part; and

"(ii) an individual who is enrolled under a group health plan or health insurance coverage offered in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act) with respect to which there is in effect an agreement with the Secretary under section 1197 with respect to such selected drug as so furnished or administered.
4(2) MAXIMUM FAIR PRICE.—The term "maximum fair price" means, with respect to a plan year during a price applicability period and with respect to a selected drug (as defined in section 1192(e)) with respect to such period, the price published pursuant to section 1195 in the Federal Register for such drug and year.

5(3) AVERAGE INTERNATIONAL MARKET PRICE DEFINED.—

"(A) IN GENERAL.—The terms "average international market price" and "AIM price" mean, with respect to a drug, the average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for a unit (as defined in paragraph (4)) of the drug for sales of such drug (calculated across different dosage forms and strengths of the drug and not based on the specific formulation or package size or package type), as computed (as of the date of publication of such drug as a selected drug under section 1192(a)) in all countries described in clause (ii) of subparagraph (B) that are applicable countries (as described in clause (ii) of such subparagraph) with respect to such drug;

"(B) APPLICABLE COUNTRIES.—

"(i) IN GENERAL.—For purposes of subparagraph (A), a country described in clause (ii) is an applicable country described in this clause with respect to a drug if there is available an average price for any unit for the drug for sales of such drug in such country.

"(ii) COUNTRIES DESCRIBED.—For purposes of this paragraph, the following are countries described in this clause:

"(i) Australia;
"(ii) Canada;
"(iii) France;
"(iv) Germany;
"(v) Japan;
"(vi) The United Kingdom;

"(4) UNITS.—The term "units" means, with respect to a drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the drug that is dispensed.

Sec. 1192. Selection of negotiation-eligible drugs as selected drugs

"(a) IN GENERAL.—Not later than the selected drug publication date with respect to an initial-price-applicability year, subject to subsection (h), the Secretary shall select and publish in the Federal Register a list of—

5(4)

"(A) with respect to an initial-price-applicability year during 2025, at least 25 negotiation-eligible drugs described in subparagraphs (A) and (B), but not subparagraph (C), of subsection (d) (or, with respect to an initial-price-applicability year during such period beginning after 2025, the maximum number (if such number
is less than twenty-five (25) of such negotiation-eligible drugs for the year) with respect to such year; and

"(B) with respect to an initial price applicability year during 2026 or a subsequent year, at least fifty (50) negotiation-eligible drugs described in subparagraphs (A) and (B); but not subparagraph (C), of subsection (d)(1) (or, with respect to an initial price applicability year during such period, the maximum number (if such number is less than fifty) of such negotiation-eligible drugs for the year) with respect to such year;

"(2) all negotiation-eligible drugs described in subparagraph (C) of such subsection with respect to such year; and

"(3) all new entrant negotiation-eligible drugs (as defined in subsection (g)(1)) with respect to such year;

Each drug published on the list pursuant to the previous sentence shall be subject to the negotiation process under section 1194 for the voluntary negotiation period with respect to such initial price applicability year and such subsequent year (and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period). In applying this subsection, any negotiation-eligible drug that is selected under this subsection for an initial price applicability year shall not count toward the required minimum amount of drugs to be selected under paragraph (4) for any subsequent year, including such a drug so selected that is subject to renegotiation under section 1194.

"(b) Selection of Drugs.—In carrying out subsection (a)(1) the Secretary shall select for inclusion on the published list described in subsection (a) with respect to a price applicability period, the negotiation-eligible drugs that the Secretary projects will result in the greatest savings to the Federal Government or fair price eligible individuals during the price applicability period. In making this projection of savings for drugs for which there is an AIM price for a price applicability period, the savings shall be projected across different dosage forms and strengths of the drugs and not based on the specific formulation or package size or package type of the drugs, taking into consideration both the volume of drugs for which payment is made, to the extent such data is available, and the amount by which the net price for the drugs exceeds the AIM price for the drugs.

"(c) Selected Drug.—For purposes of this part, each drug included on the list published under subsection (a) with respect to an initial price applicability year shall be referred to as a "selected drug" with respect to such year and each subsequent plan year beginning after the first plan year beginning after the date on which the Secretary determines two or more drug products—

"(1) are approved or licensed (as applicable) —

"(A) under section 505(j) of the Federal Food, Drug, and Cosmetic Act using such drug as the listed drug; or

"(B) under section 351(k) of the Public Health Service Act using such drug as the reference product; and

"(2) continue to be marketed;

"(d) Negotiation-eligible Drug—
(4) IN GENERAL.—For purposes of this part, the term "negotiation-eligible drug" means, with respect to the selected drug publication date with respect to an initial-price applicability year, a qualifying single-source drug, as defined in subsection (e), that meets any of the following criteria:

(A) COVERED PART D DRUGS.—The drug is among the 125 covered part D drugs (as defined in section 1869D–2(e)) for which there was an estimated greatest net spending under parts C and D of title XVIII, as determined by the Secretary, during the most recent plan year prior to such drug publication date for which data are available.

(B) OTHER DRUGS.—The drug is among the 125 drugs for which there was an estimated greatest net spending in the United States (including the 50 States, the District of Columbia, and the territories of the United States), as determined by the Secretary, during the most recent plan year prior to such drug publication date for which data are available.

(C) INSULIN.—The drug is a qualifying single-source drug described in subsection (e)(3).

(2) CLARIFICATION.—In determining whether a qualifying single-source drug satisfies any of the criteria described in paragraph (1), the Secretary shall, to the extent practicable, use data that is aggregated across dosage forms and strengths of the drug and not based on the specific formulation or package size or package type of the drug.

(3) PUBLICATION.—Not later than the selected drug publication date with respect to an initial-price applicability year, the Secretary shall publish in the Federal Register a list of negotiation-eligible drugs with respect to such selected drug publication date.

(e) QUALIFYING SINGLE SOURCE DRUG.—For purposes of this part, the term "qualifying single-source drug" means any of the following:

(1) DRUG PRODUCTS.—A drug that—

(A) is approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act and continues to be marketed pursuant to such approval; and

(B) is not the listed drug for any drug that is approved and continues to be marketed under section 505(j) of such Act.

(2) BIOLOGICAL PRODUCTS.—A biological product that—

(A) is licensed under section 351(a) of the Public Health Service Act, including any product that has been deemed to be licensed under section 351 of such Act pursuant to section 7802(e)(4) of the Biologies Price Competition and Innovation Act of 2000; and continues to be marketed under section 351 of such Act; and

(B) is not the reference product for any biological product that is licensed and continues to be marketed under section 351(k) of such Act.

(3) INSULIN PRODUCT.—Notwithstanding paragraphs (1) and (2), any insulin product that is approved under subsection (c) or (f) of section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under subsection (a) or (k) of section 351 of the Public Health Service Act and continues to be marketed under such section 505 or 351, including any...
insulin—product that has been deemed to be licensed under section 351(a) of the Public Health Service Act pursuant to section 7002(e)(4) of the Biologies Price Competition and Innovation Act of 2003 and continues to be marketed pursuant to such licensure.

For purposes of applying paragraphs (1) and (2), a drug or biological product that is marketed by the same sponsor or manufacturer (or an affiliate thereof or a cross-licensed producer or distributor) as the listed drug or reference product described in such respective paragraph shall not be taken into consideration:

"(f) INFORMATION ON INTERNATIONAL DRUG PRICES.—For purposes of determining which negotiation-eligible drugs to select under subsection (a) and, in the case of such drugs that are selected drugs, to determine the maximum fair-price for such a drug and whether such maximum fair-price should be renegotiated under section 1194, the Secretary shall use data relating to the AIM price with respect to such drug as available or provided to the Secretary and shall on an ongoing basis request from manufacturers of selected drugs information on the AIM price of such a drug:

"(g) NEW-ENTRANT NEGOTIATION-ELIGIBLE DRUGS.—

"(1) IN GENERAL.—For purposes of this part, the term "new-entrant negotiation-eligible drug" means, with respect to the selected drug publication date with respect to an initial price applicability year, a qualifying single source drug—

"(A) that is first approved or licensed, as described in paragraph (1), (2), or (3) of subsection (e), as applicable, during the year preceding such selected drug publication date; and

"(B) that the Secretary determines under paragraph (2) is likely to be included as a negotiation-eligible drug with respect to the subsequent selected drug publication date:

"(2) DETERMINATION.—In the case of a qualifying single source drug that meets the criteria described in subparagraph (A) of paragraph (1), with respect to an initial price applicability year, if the wholesale acquisition cost at which such drug is first marketed in the United States is equal to or greater than the median household income (as determined according to the most recent data collected by the United States Census Bureau), the Secretary shall determine before the selected drug publication date with respect to the initial price applicability year, if the drug is likely to be included as a negotiation-eligible drug with respect to the subsequent selected drug publication date; based on the projected spending under title XVIII or in the United States on such drug. For purposes of this paragraph the term "United States" includes the 50 States, the District of Columbia, and the territories of the United States.

"(h) CONFLICT OF INTEREST.—

"(1) IN GENERAL.—In the case the Inspector General of the Department of Health and Human Services determines the Secretary has a conflict, with respect to a matter described in paragraph (2), the individual described in paragraph (3) shall carry out the duties of the Secretary under this part, with respect to a negotiation-eligible drug, that would otherwise be such a conflict.

"(2) MATTER DESCRIBED.—A matter described in this paragraph is—
"(A) a financial interest (as described in section 2635.402 of title 5, Code of Federal Regulations, as in effect on the date of the enactment of this section; (except for an interest described in subsection (b)(2)(iv) of such section)) on the date of the selected drug publication date, with respect to the price applicability year (as applicable);

"(B) a personal or business relationship (as described in section 2635.502 of such title) on the date of the selected drug publication date, with respect to the price applicability year;

"(C) employment by a manufacturer of a negotiation eligible drug during the preceding 10-year period beginning on the date of the selected drug publication date, with respect to each price applicability year; and

"(D) any other matter the General Counsel determines appropriate.

"(3) INDIVIDUAL DESCRIBED.—An individual described in this paragraph is—

"(A) the highest-ranking officer or employee of the Department of Health and Human Services (as determined by the organizational chart of the Department) that does not have a conflict under this subsection; and

"(B) is nominated by the President and confirmed by the Senate with respect to the position.

"Sec. 1193. Manufacturer agreements

"(a) IN GENERAL.—For purposes of section 1194(a)(2), the Secretary shall enter into agreements with manufacturers of selected drugs with respect to a price applicability period, by not later than June 15 following the selected drug publication date with respect to such selected drug, under which—

"(1) during the voluntary negotiation period for the initial price applicability year for the selected drug, the Secretary and manufacturer, in accordance with section 1194, negotiate to determine (and, by not later than the last date of such period and in accordance with subsection (c), agree to) a maximum fair price for such selected drug of the manufacturer in order to provide access to such price—

"(A) to fair price eligible individuals who with respect to such drug are described in subparagraph (A) of section 1194(c)(1) and are furnished or dispensed such drug during; subject to subparagraph (2), the price applicability period; and

"(B) to hospitals, physicians, and other providers of services and suppliers with respect to fair price eligible individuals who with respect to such drug are described in subparagraph (B) of such section and are furnished or administered such drug during; subject to subparagraph (2), the price applicability period;

"(2) the Secretary and the manufacturer shall, in accordance with a process and during a period specified by the Secretary pursuant to rulemaking, renegotiate (and, by not later than the last date of such period and in accordance with subsection (c), agree to) the maximum fair price for such drug if the Secretary determines that there is a material change in any of the factors described in section 1194(d) relating to the drug; including
changes in the AIM price for such drug, in order to provide access to such maximum fair price (as so renegotiated)——

"(A) to fair-price eligible individuals who with respect to such drug are described in subparagraph (A) of section 1191(c)(1) and are furnished or dispensed such drug during any year during the price-applicability period (beginning after such renegotiation) with respect to such selected drug; and

"(B) to hospitals, physicians, and other providers of services and suppliers with respect to fair-price eligible individuals who with respect to such drug are described in subparagraph (B) of such section and are furnished or administered such drug during any year described in subparagraph (A);"

"(3) the maximum fair price (including as renegotiated pursuant to paragraph (2)); with respect to such a selected drug, shall be provided to fair-price eligible individuals, who with respect to such drug are described in subparagraph (A) of section 1191(c)(1), at the pharmacy or by a mail order service at the point of sale of such drug;

"(4) the manufacturer, subject to subsection (d), submits to the Secretary, in a form and manner specified by the Secretary——

"(A) for the voluntary negotiation period for the price-applicability period (and, if applicable, before any period of renegotiation specified pursuant to paragraph (2)) with respect to such drug all information that the Secretary requires to carry out the negotiation (or renegotiation process) under this part, including information described in section 1192(f) and section 1194(d)(1); and

"(B) on an ongoing basis, information on changes in prices for such drug that would affect the AIM price for such drug or otherwise provide a basis for renegotiation of the maximum fair price for such drug pursuant to paragraph (2);

"(5) the manufacturer agrees that in the case the selected drug of a manufacturer is a drug described in subsection (e), the manufacturer will, in accordance with such subsection, make any payment required under such subsection with respect to such drug; and

"(6) the manufacturer complies with requirements imposed by the Secretary for purposes of administering the program, including with respect to the duties described in section 1196;

"(b) AGREEMENT IN EFFECT UNTIL DRUG IS NO LONGER A SELECTED DRUG.— An agreement entered into under this section shall be effective, with respect to a drug, until such drug is no longer considered a selected drug under section 1192(c);

"(c) SPECIAL RULE FOR CERTAIN SELECTED DRUGS WITHOUT AIM PRICE.—

"(1) IN GENERAL.— In the case of a selected drug for which there is no AIM price available with respect to the initial-price-applicability year for such drug and for which an AIM price becomes available beginning with respect to a subsequent plan year during the price-applicability period for such drug, if the Secretary determines the amount described in paragraph (2)(A) for a unit of such drug is greater than the amount described in paragraph (2)(B) for a unit of such drug, then by not later than one year after the date
of such determination, the manufacturer of such selected drug shall pay to the Treasury an amount equal to the product of—

"(A) the difference between such amount described in paragraph (2)(A) for a unit of such drug and such amount described in paragraph (2)(B) for a unit of such drug; and

"(B) the number of units of such drug sold in the United States, including the 50 States, the District of Columbia, and the territories of the United States, during the period described in paragraph (2)(B);

"(2) Amounts described—

"(A) Weighted average price before AIM price available.—For purposes of paragraph (1), the amount described in this subparagraph for a selected drug described in such paragraph is the amount equal to the weighted average manufacturer price (as defined in section 1927(k)(11)) for such dosage strength and form for the drug during the period beginning with the first plan year for which the drug is included on the list of negotiation eligible drugs published under section 1192(d) and ending with the last plan year during the price applicability period for such drug with respect to which there is no AIM price available for such drug;

"(B) Amount multiplier after AIM price available.—For purposes of paragraph (1), the amount described in this subparagraph for a selected drug described in such paragraph is the amount equal to 200 percent of the AIM price for such drug with respect to the first plan year during the price applicability period for such drug with respect to which there is an AIM price available for such drug.

"(C) Confidentiality of information.—Information submitted to the Secretary under this part by a manufacturer of a selected drug that is proprietary information of such manufacturer (as determined by the Secretary) may be used only by the Secretary or disclosed to and used by the Comptroller General of the United States or the Medicare Payment Advisory Commission for purposes of carrying out this part.

"(D) Regulations—

"(4) In general.—The Secretary shall, pursuant to rulemaking, specify, in accordance with paragraph (2), the information that must be submitted under subsection (a)(4).

"(2) Information specified.—Information described in paragraph (1), with respect to a selected drug, shall include information on sales of the drug (by the manufacturer of the drug or by another entity under license or other agreement with the manufacturer, with respect to the sales of such drug, regardless of the name under which the drug is sold) in any foreign country that is part of the AIM price. The Secretary shall verify, to the extent practicable, such sales from appropriate officials of the government of the foreign country involved.

"(F) Compliance with requirements for administration of program.—Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under section 1196(e)(1), as applicable, for purposes of administering the program.
"Sec. 1194. Negotiation and renegotiation process

(a) IN GENERAL.— For purposes of this part, under an agreement under section 1193 between the Secretary and a manufacturer of a selected drug, with respect to the period for which such agreement is in effect and in accordance with subsections (b) and (c), the Secretary and the manufacturer—

(1) shall during the voluntary negotiation period with respect to the initial price applicability year for such drug, in accordance with this section, negotiate a maximum fair price for such drug for the purpose described in section 1193(a)(1); and

(2) as applicable pursuant to section 1193(a)(2) and in accordance with the process specified pursuant to such section, renegotiate such maximum fair price for such drug for the purpose described in such section.

(b) Negotiating methodology and objective.—

(1) IN GENERAL.— The Secretary shall develop and use a consistent methodology for negotiations under subsection (a) that, in accordance with paragraph (2) and subject to paragraph (3), achieves the lowest maximum fair price for each selected drug while appropriately rewarding innovation.

(2) Prioritizing factors.— In considering the factors described in subsection (d) in negotiating (and, as applicable, renegotiating) the maximum fair price for a selected drug, the Secretary shall, to the extent practicable, consider all of the available factors listed but shall prioritize the following factors:

(A) Research and development costs.—The factor described in paragraph (1)(A) of such subsection.

(B) Market data.—The factor described in paragraph (1)(B) of such subsection.

(C) Unit costs of production and distribution.—The factor described in paragraph (1)(C) of such subsection.

(D) Comparison to existing therapeutics—alternatives.—The factor described in paragraph (2)(A) of such subsection.

(3) Requirement.—

(A) IN GENERAL.— In negotiating the maximum fair price of a selected drug, with respect to an initial price applicability year for the selected drug, and, as applicable, in renegotiating the maximum fair price for such drug, with respect to a subsequent year during the price applicability period for such drug, in the case that the manufacturer of the selected drug offers under the negotiation or renegotiation, as applicable, a price for such drug that is not more than the target price described in subparagraph (B) for such drug for the respective year, the Secretary shall agree under such negotiation or renegotiation, respectively, to such offered price as the maximum fair price.

(B) Target price.—

(i) IN GENERAL.— Subject to clause (ii), the target price described in this subparagraph for a selected drug with respect to a year, is the average price
(which shall be the net average price, if practicable, and volume-weighted, if
practicable) for a unit of such drug for sales of such drug, as computed (across
different dosage forms and strengths of the drug and not based on the specific
formulation or package size or packaging type of the drug) in the applicable
country described in section 1121(e)(3)(B) with respect to such drug that, with
respect to such year, has the lowest average price for such drug as compared to
the average prices (as so computed) of such drug with respect to such year in
the other applicable countries described in such section with respect to such
drug:

"(ii) SELECTED DRUGS WITHOUT AIM PRICE.—In applying this paragraph in
the case of negotiating the maximum fair price of a selected drug for which there
is no AIM price available with respect to the initial price applicability year for
such drug; or, as applicable, renegotiating the maximum fair price for such drug
with respect to a subsequent year during the price applicability period for such
drug before the first plan year for which there is an AIM price available for such
drug, the target price described in this subparagraph for such drug and
respective year is the amount that is 80 percent of the average manufacturer
price (as defined in section 1927(h)(1)) for such drug and year.

"(c) LIMITATION.—

"(1) IN GENERAL.—Subject to paragraph (2), the maximum fair price negotiated
(including as renegotiated) under this section for a selected drug, with respect to each
plan year during a price applicability period for such drug, shall not exceed 120 percent of
the AIM price applicable to such drug with respect to such year:

"(2) SELECTED DRUGS WITHOUT AIM PRICE.—In the case of a selected drug for
which there is no AIM price available with respect to the initial price applicability year for
such drug, for each plan year during the price applicability period before the first plan year
for which there is an AIM price available for such drug, the maximum fair price negotiated
(including as renegotiated) under this section for the selected drug shall not exceed the
amount equal to 80 percent of the average manufacturer price for the drug with respect to
such year:

"(d) CONSIDERATIONS.—For purposes of negotiating and, as applicable, renegotiating
(including for purposes of determining whether to renegotiate) the maximum fair price of a
selected drug under this part with the manufacturer of the drug, the Secretary, consistent with
subsection (b)(2), shall take into consideration the factors described in paragraphs (1), (2), (3),
and (5), and may take into consideration the factor described in paragraph (4):

"(1) MANUFACTURER-SPECIFIC INFORMATION.—The following information, including
as submitted by the manufacturer:

"(A) Research and development costs of the manufacturer for the drug and the
extent to which the manufacturer has recouped research and development costs:

"(B) Market data for the drug, including the distribution of sales across different
firms and purchasers and projected future revenues for the drug;

"(C) Unit costs of production and distribution of the drug:
"(D) Prior Federal financial support for novel therapeutic discovery and development with respect to the drug;

"(E) Data on patents and on existing and pending exclusivity for the drug;

"(F) National sales data for the drug;

"(G) Information on clinical trials for the drug in the United States or in applicable countries described in section 1191(e)(3)(B);

"(2) INFORMATION ON ALTERNATIVE PRODUCTS.—The following information:

"(A) The extent to which the drug represents a therapeutic advance as compared to existing therapeutic alternatives and, to the extent such information is available, the costs of such existing therapeutic alternatives;

"(B) Information on approval by the Food and Drug Administration of alternative drug products;

"(C) Information on comparative effectiveness analysis for such products, taking into consideration the effects of such products on specific populations, such as individuals with disabilities, the elderly, terminally ill, children, and other patient populations.

In considering information described in subparagraph (G), the Secretary shall not use evidence or findings from comparative clinical effectiveness research in a manner that treats extending the life of an elderly, disabled, or terminally ill individual as of lesser value than extending the life of an individual who is younger, nondisabled, or not terminally ill. Nothing in the previous sentence shall affect the application or consideration of an AIM price for a selected drug;

"(3) FOREIGN SALES INFORMATION.—To the extent available on a timely basis, including as provided by a manufacturer of the selected drug or otherwise, information on sales of the selected drug in each of the countries described in section 1191(e)(3)(B);

"(4) VA DRUG PRICING INFORMATION.—Information disclosed to the Secretary pursuant to subsection (f);

"(5) ADDITIONAL INFORMATION.—Information submitted to the Secretary, in accordance with a process specified by the Secretary, by other parties that are affected by the establishment of a maximum fair price for the selected drug;

"(e) REQUEST FOR INFORMATION.—For purposes of negotiating and, as applicable, renegotiating (including for purposes of determining whether to renegotiate) the maximum fair price of a selected drug under this part with the manufacturer of the drug, with respect to a price applicability period, and other relevant data for purposes of this section—

"(1) the Secretary shall, not later than the selected drug publication date with respect to the initial price applicability year of such period, request drug pricing information from the manufacturer of such selected drug, including information described in subsection (d)

(1); and

"(2) by not later than October 1 following the selected drug publication date, the manufacturer of such selected drug shall submit to the Secretary such requested information in such form and manner as the Secretary may require.
The Secretary shall request, from the manufacturer or others, such additional information as may be needed to carry out the negotiation and renegotiation process under this section.

"(f) DISCLOSURE OF INFORMATION.—For purposes of this part, the Secretary of Veterans Affairs may disclose to the Secretary of Health and Human Services the price of any negotiation-eligible drug that is purchased pursuant to section 1126 of title 38, United States Code:

"Sec. 1195. Publication of maximum fair prices

"(a) IN GENERAL.—With respect to an initial price applicability year and selected drug with respect to such year, not later than April 1 of the plan year prior to such initial price applicability year, the Secretary shall publish in the Federal Register the maximum fair price for such drug negotiated under this part with the manufacturer of such drug.

"(b) UPDATES.—

"(1) SUBSEQUENT YEAR MAXIMUM FAIR PRICES.—For a selected drug, for each plan year subsequent to the initial price applicability year for such drug with respect to which an agreement for such drug is in effect under section 1193, the Secretary shall publish in the Federal Register—

"(A) subject to subparagraph (B), the amount equal to the maximum fair price published for such drug for the previous year, increased by the annual percentage increase in the consumer price index for all urban consumers (all items; U.S. city average) as of September of such previous year; or

"(B) in the case the maximum fair price for such drug was renegotiated, for the first year for which such price as so renegotiated applies, such renegotiated maximum fair price.

"(2) PRICES NEGOTIATED AFTER DEADLINE.—In the case of a selected drug with respect to an initial price applicability year for which the maximum fair price is determined under this part after the date of publication under this section, the Secretary shall publish such maximum fair price in the Federal Register not later than 30 days after the date such maximum price is so determined.

"Sec. 1196. Administrative duties; coordination provisions

"(a) ADMINISTRATIVE DUTIES.—

"(1) IN GENERAL.—For purposes of section 1101, the administrative duties described in this section are the following:

"(A) The establishment of procedures (including through agreements with manufacturers under this part, contracts with prescription drug plans under part D of title XVIII and MA–PD plans under part C of such title, and agreements under section 1497 with group health plans and health insurance issuers of health insurance coverage offered in the individual or group market) under which the maximum fair price for a selected drug is provided to fair-price eligible individuals, who with respect to such drug are described in paragraph (A) of section 1194(c)(1), at pharmacies or by mail-order service at the point-of-sale of the drug for the applicable price period.
for such drug and providing that such maximum fair price is used for determining cost-sharing under such plans or coverage for the selected drug:

"(B) The establishment of procedures (including through agreements with manufacturers under this part and contracts with hospitals, physicians, and other providers of services and suppliers and agreements under section 1107 with group health plans and health insurance issuers of health insurance coverage offered in the individual or group market) under which, in the case of a selected drug furnished or administered by such a hospital, physician, or other provider of services or supplier to fair-price eligible individuals (who with respect to such drug are described in subparagraph (B) of section 1101(e)(1)), the maximum fair price for the selected drug is provided to such hospitals, physicians, and other providers of services and suppliers (as applicable) with respect to such individuals and providing that such maximum fair price is used for determining cost-sharing under the respective part, plan, or coverage for the selected drug:

"(C) The establishment of procedures (including through agreements and contracts described in subparagraphs (A) and (B)) to ensure that, not later than 90 days after the dispensing of a selected drug to a fair-price eligible individual by a pharmacy or mail order service, the pharmacy or mail order service is reimbursed for an amount equal to the difference between—

"(i) the lesser of—

"(i) the wholesale acquisition cost of the drug;

"(ii) the national average drug acquisition cost of the drug; and

"(iii) any other similar determination of pharmacy acquisition costs of the drug as determined by the Secretary; and

"(ii) the maximum fair price for the drug:

"(D) The establishment of procedures to ensure that the maximum fair price for a selected drug is applied before—

"(i) any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of fair-price eligible individuals as the Secretary may specify; and

"(ii) any other discounts:

"(E) The establishment of procedures to enter into appropriate agreements and protocols for the ongoing computation of AIM prices for selected drugs, including, to the extent possible, to compute the AIM price for selected drugs and including by providing that the manufacturer of such a selected drug should provide information for such computation not later than 3 months after the first date of the voluntary negotiation period for such selected drug:

"(F) The establishment of procedures to compute and apply the maximum fair price across different strengths and dosage forms of a selected drug and not based on the specific formulation or package size or package type of the drug:
"(G) The establishment of procedures to negotiate and apply the maximum fair price in a manner that does not include any dispensing or similar fee.

"(H) The establishment of procedures to carry out the provisions of this part, as applicable, with respect to:

"(i) Fair-price eligible individuals who are enrolled under a prescription drug plan under part D of title XVIII or an MA–PD plan under part C of such title;

"(ii) Fair-price eligible individuals who are enrolled under a group health plan or health insurance coverage offered by a health insurance issuer in the individual or group market with respect to which there is an agreement in effect under section 1197; and

"(iii) Fair-price eligible individuals who are entitled to benefits under part A of title XVIII or enrolled under part B of such title;

"(I) The establishment of a negotiation process and renegotiation process in accordance with section 1194, including a process for acquiring information described in subsection (d) of such section and determining amounts described in subsection (b) of such section:

"(d) The provision of a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, fair-price eligible individuals, and the third party with a contract under subsection (c)(1);

"(2) Monitoring Compliance.—

"(A) In general.— The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under section 1193, including by establishing a mechanism through which violations of such terms may be reported.

"(B) Notification.— If a third party with a contract under subsection (c)(1) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such noncompliance for appropriate enforcement under section 4192 of the Internal Revenue Code of 1986 or section 1198, as applicable.

"(b) Collection of Data.—

"(1) From Prescription Drug Plans and MA–PD Plans.— The Secretary may collect appropriate data from prescription drug plans under part D of title XVIII and MA–PD plans under part C of such title in a timeframe that allows for maximum fair prices to be provided under this part for selected drugs.

"(2) From Health Plans.— The Secretary may collect appropriate data from group health plans or health insurance issuers offering group or individual health insurance coverage in a timeframe that allows for maximum fair prices to be provided under this part for selected drugs.

"(3) Coordination of Data Collection.— To the extent feasible, as determined by the Secretary, the Secretary shall ensure that data collected pursuant to this subsection is coordinated with, and not duplicative of, other Federal data collection efforts.

"(c) Contract with Third Parties.—
"(1) IN GENERAL.— The Secretary may enter into a contract with 1 or more third parties to administer the requirements established by the Secretary in order to carry out this part. At a minimum, the contract with a third party under the preceding sentence shall require that the third party—

(A) receive and transmit information between the Secretary, manufacturers, and other individuals or entities the Secretary determines appropriate;

(B) receive, distribute, or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to meet the obligations of manufacturers under agreements under this part;

(C) provide adequate and timely information to manufacturers, consistent with the agreement with the manufacturer under this part, as necessary for the manufacturer to fulfill its obligations under this part; and

(D) permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program;

(2) PERFORMANCE REQUIREMENTS.— The Secretary shall establish performance requirements for a third party with a contract under paragraph (1) and safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this part.

"Sec. 1197. Voluntary participation by other health plans

(e) AGREEMENT TO PARTICIPATE UNDER PROGRAM.—

(1) IN GENERAL.— Subject to paragraph (2), under the program under this part the Secretary shall be treated as having in effect an agreement with a group health plan or health insurance issuer offering group or individual health insurance coverage (as such terms are defined in section 2701 of the Public Health Service Act), with respect to a price applicability period and a selected drug with respect to such period—

(A) with respect to such selected drug furnished or dispensed at a pharmacy or by mail-order service if coverage is provided under such plan or coverage during such period for such selected drug as so furnished or dispensed; and

(B) with respect to such selected drug furnished or administered by a hospital, physician, or other provider of services or supplier if coverage is provided under such plan or coverage during such period for such selected drug as so furnished or administered;

(2) OPTING OUT OF AGREEMENT.— The Secretary shall not be treated as having in effect an agreement under the program under this part with a group health plan or health insurance issuer offering group or individual health insurance coverage with respect to a price applicability period and a selected drug with respect to such period if such a plan or issuer affirmatively elects, through a process specified by the Secretary, not to participate under the program with respect to such period and drug;

(f) EXCLUSION OF ELECTION.— With respect to each price applicability period and each selected drug with respect to such period, the Secretary and the Secretary of Labor and the
Secretary of the Treasury, as applicable, shall make public a list of each group-health-plan-end each health-insurance issuer offering group or individual health-insurance coverage, with respect to which coverage is provided under such plan or coverage for such drug, that has elected under subsection (e) not to participate under the program with respect to such period and drug.

"Sec. 1198. Civil monetary penalty"

"(a) Violations relating to offering of maximum fair price.—Any manufacturer of a selected drug that has entered into an agreement under section 1193, with respect to a plan year during the price applicability period for such drug, that does not provide access to a price that is not more than the maximum fair price (or a lesser price) for such drug or such year—

"(1) to a fair-price-eligible individual who, with respect to such drug, is described in subparagraph (A) of section 1194(c)(1) and who is furnished or dispensed such drug during such year; or

"(2) to a hospital, physician, or other provider of services or supplier with respect to fair-price-eligible individuals who with respect to such drug is described in subparagraph (B) of such section and is furnished or administered such drug by such hospital, physician, or provider or supplier during such year;

shall be subject to a civil monetary penalty equal to ten times the amount equal to the difference between the price for such drug made available for such year by such manufacturer with respect to such individual or hospital, physician, provider, or supplier and the maximum fair price for such drug for such year.

"(b) Violations of certain terms of agreement.—Any manufacturer of a selected drug that has entered into an agreement under section 1193, with respect to a plan year during the price applicability period for such drug, that is in violation of a requirement imposed pursuant to section 1193(a)(6) shall be subject to a civil monetary penalty of not more than $1,000,000 for each such violation.

"(c) Application.—The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil monetary penalty under this section in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a):"

"Sec. 1199. Miscellaneous provisions"

"(a) Paperwork Reduction Act.—Chapter 35 of title 44, United States Code, shall not apply to data collected under this part.

"(b) Limitation on judicial review.—The following shall not be subject to judicial review:

"(1) The selection of drugs for publication under section 1192(a);"

"(2) The determination of whether a drug is a negotiation-eligible drug under section 1192(d);"

"(3) The determination of the maximum fair price of a selected drug under section 1194(c)(1);"

"(4) The determination of units of a drug for purposes of section 1191(c)(3):"
(e) Coordination.—In carrying out this part with respect to group health plans or health
insurance coverage offered in the group market that are subject to oversight by the Secretary
of Labor or the Secretary of the Treasury, the Secretary of Health and Human Services shall
coordinate with such respective Secretary:

"(d) Data Sharing.—The Secretary shall share with the Secretary of the Treasury such
information as is necessary to determine the tax imposed by section 4192 of the Internal
Revenue Code of 1986.".

(b) Application of Maximum Fair Prices and Conforming Amendments.—

(A) Application to Payments under Part B.—Section 1847A(b)(1)(B) of the
Social Security Act (42 U.S.C. 1395w–3(a)(b)(1)(B)) is amended by inserting "or in the
case of such a drug or biological that is a selected drug (as defined in section
4192(c)), with respect to a price applicability period (as defined in section 1191(b)(2)),
406 percent of the maximum fair price (as defined in section 1191(c)(2)) applicable
for such drug and a plan year during such period" after "paragraph (4)".

(B) Exception to Part D Non-Interference.—Section 1860D–11(i) of the
Social Security Act (42 U.S.C. 1395w–111(i)) is amended by inserting ", except as
provided under part E of title XI" after "the Secretary".

(C) Application as Negotiated Price under Part D.—Section 1860D–2(d)(1)
of the Social Security Act (42 U.S.C. 1395w–102(d)(1)) is amended—

(i) in subparagraph (B), by inserting ", subject to subparagraph (D)," after "negotiated prices"; and

(ii) by adding at the end the following new subparagraph:

"(D) Application of Maximum Fair Price for Selected Drugs.—In
applying this section, in the case of a covered part D drug that is a selected
drug (as defined in section 1192(c)), with respect to a price applicability
period (as defined in section 1191(b)(2)), the negotiated prices used for
payment (as described in this subsection) shall be the maximum fair price
(as defined in section 1191(c)(2)) for such drug and for each plan year
during such period.".

(D) Information from Prescription Drug Plans and MA–PD Plans
Required.—

(i) Prescription Drug Plans.—

Section 1860D–12(b) of the Social Security Act (42 U.S.C. 1395w–112(b)) is
amended by adding at the end the following new paragraph:

"(D) Provision of Information Related to Maximum Fair Prices.—
Each contract entered into with a PDP sponsor under this part with respect
to a prescription drug plan offered by such sponsor shall require the
sponsor to provide information to the Secretary as requested by the
Secretary in accordance with section 1196(b).".

(ii) MA–PD Plans.—
Section 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w–27(f)(3)) is amended by adding at the end the following new subparagraph:

"(E) Provision of information related to maximum fair prices.—
Section 1860D–12(b)(8).

(2) DRUG GROUP HEALTH PLANS AND HEALTH INSURANCE COVERAGE.—

(A) PHSA.—

Part D of title XXVII of the Public Health Service Act (42 U.S.C. 300gg–141 et seq.) is amended by adding at the end the following new section:

"Sec. 2799A–11. Fair Price Negotiation Program and application of maximum fair prices

"(a) In general.—In the case of a group health plan or health insurance issuer offering group or individual health insurance coverage that is treated under section 1107 of the Social Security Act as having in effect an agreement with the Secretary under the Fair Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(e) of such Act) with respect to such period with respect to which coverage is provided under such plan or coverage—

"(1) the provisions of such part shall apply—

"(A) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or dispensed at a pharmacy or by a mail order service, to the plans or coverage offered by such plan or issuer, and to the individuals enrolled under such plans or coverage, during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA–PD plans, and to individuals enrolled under such prescription drug plans and MA–PD plans during such period; and

"(B) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier, to the plans or coverage offered by such plan or issuer, to the individuals enrolled under such plans or coverage, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary, to individuals entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period;

"(2) the plan or issuer shall apply any cost-sharing responsibilities under such plan or coverage, with respect to such selected drug, by substituting an amount not more than the maximum fair price negotiated under such part E of title XI for such drug in lieu of the drug price upon which the cost-sharing would
have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and

"(3) the Secretary shall apply the provisions of such part to such plan, issuer, and coverage, such individuals so enrolled in such plans and coverage, and such hospitals, physicians, and other providers and suppliers participating in such plans and coverage;

"(b) Notification Regarding Nonparticipation in Fair-Price Negotiation Program.—A group health plan or a health insurance issuer offering group or individual health insurance coverage shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1197 of the Social Security Act by the plan or issuer to not participate in the Fair-Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act) for which coverage is provided under such plan or coverage before the beginning of the plan year for which such election was made;¹:

(B) ERISA:—

(i) IN GENERAL.—

Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1181 et seq.) is amended by adding at the end the following new section:

"Sec. 726. Fair-Price Negotiation Program and application of maximum fair prices

"(a) IN GENERAL.—In the case of a group health plan or health insurance issuer offering group health insurance coverage that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary under the Fair-Price Negotiation Program under part E of title XI of such Act, with respect to a price applicability period (as defined in section 1191(b) of such Act) and a selected drug (as defined in section 1192(c) of such Act) with respect to such period with respect to which coverage is provided under such plan or coverage—

"(1) the provisions of such part shall apply, as applicable—

"(A) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or dispensed at a pharmacy or by a mail-order service, to the plans or coverage offered by such plan or issuer, and to the individuals enrolled under such plans or coverage; during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA-PD plans, and to individuals enrolled under such prescription drug plans and MA-PD plans during such period; and

"(B) if coverage of such selected drug is provided under such plan or coverage if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier to the plans or
coverage offered by such plan or issuer, to the individuals enrolled under such plans or coverage, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary, to individuals entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under title XVIII during such period;

"(2) the plan or issuer shall apply any cost-sharing responsibilities under such plan or coverage, with respect to such selected drug, by substituting an amount not more than the maximum fair-price-negotiated under such part E of title XI for such drug in lieu of the drug price upon which the cost-sharing would have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and

"(3) the Secretary shall apply the provisions of such part E to such plan, issuer, and coverage, and such individuals so enrolled in such plans:

"(b) Notification regarding nonparticipation in Fair Price Negotiation Program.—A group health plan or a health insurance issuer offering group health insurance coverage shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1107 of the Social Security Act by the plan or issuer to not participate in the Fair Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(c) of such Act) for which coverage is provided under such plan or coverage before the beginning of the plan year for which such election was made;”.

(ii) Application to Retiree and Certain Small Group Health Plans.—Section 732(a) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1104(a)(1)) is amended by striking “section 741 and 728” and inserting “sections 741 and 726”:

(iii) Clerical Amendment.—The table of sections for subpart B of part 7 of subtitle B of title 1 of the Employee Retirement Income Security Act of 1974 is amended by adding at the end the following:

“Sec. 728. Fair Price Negotiation Program and application of maximum fair prices.”:

(G) IRC.—

(i) In General.—
Subchapter B of chapter 14 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:
Sec. 9826. Fair Price Negotiation Program and application of maximum fair prices

(a) In general.—In the case of a group health plan that is treated under section 1197 of the Social Security Act as having in effect an agreement with the Secretary under the Fair Price Negotiation Program under part E of title XI of such Act, with respect to a price-applicability period (as defined in section 1101(b) of such Act) and a selected drug (as defined in section 1192(e) of such Act) with respect to such period with respect to which coverage is provided under such plan—

"(1) the provisions of such part shall apply, as applicable—

"(A) if coverage of such selected drug is provided under such plan if the drug is furnished or dispensed at a pharmacy or by a mail-order service, to the plan, and to the individuals enrolled under such plan during such period, with respect to such selected drug, in the same manner as such provisions apply to prescription drug plans and MA–PD plans, and to individuals enrolled under such prescription drug plans and MA–PD plans during such period; and

"(B) if coverage of such selected drug is provided under such plan if the drug is furnished or administered by a hospital, physician, or other provider of services or supplier, to the plan, to the individuals enrolled under such plan, and to hospitals, physicians, and other providers of services and suppliers during such period, with respect to such drug in the same manner as such provisions apply to the Secretary, to individuals entitled to benefits under part A of title XVIII or enrolled under part B of such title, and to hospitals, physicians, and other providers and suppliers participating under such title XVIII during such period;

"(2) the plan shall apply any cost-sharing responsibilities under such plan, with respect to such selected drug, by substituting an amount not more than the maximum fair price negotiated under such part E of title XI for such drug in lieu of the drug-price upon which the cost-sharing would have otherwise applied, and such cost-sharing responsibilities with respect to such selected drug may not exceed such maximum fair price; and

"(3) the Secretary shall apply the provisions of such part E to such plan and such individuals so enrolled in such plan:

(b) Notification regarding nonparticipation in Fair Price Negotiation Program.—A group health plan shall publicly disclose in a manner and in accordance with a process specified by the Secretary any election made under section 1197 of the Social Security Act by the plan to not participate in the Fair Price Negotiation Program under part E of title XI of such Act with respect to a selected drug (as defined in section 1192(e) of such Act) for
which coverage is provided under such plan before the beginning of the plan year for which such election was made."

(ii) APPLICATION TO RETIREE AND CERTAIN SMALL GROUP HEALTH PLANS.—
Section 9831(a)(2) of the Internal Revenue Code of 1986 is amended by inserting "other than with respect to section 9826," before "any group health plan":

(iii) CLERICAL AMENDMENT.—
The table of sections for subchapter B of chapter 409 of such Code is amended by adding at the end the following new item:

"Sec. 9826. Fair-Price Negotiation Program and application of maximum fair prices."

(3) FAIR-PRICE NEGOTIATION PROGRAM PRICES INCLUDED IN BEST PRICE AND AMP.—
Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) is amended—
(A) in subsection (c)(1)(G)(i)—
(i) in subclause (III), by striking at the end ";" and ";
(ii) in subclause (IV), by striking at the end the period and inserting "; and "; and
(iii) by adding at the end the following new subclause:
"(V) in the case of a rebate period and a covered outpatient drug that is a selected drug (as defined in section 1192(c)) during such rebate period, shall be inclusive of the price for such drug made available from the manufacturer during the rebate period by reason of application of part E of title XI to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States;"); and
(B) in subsection (k)(1)(B), by adding at the end the following new clause:
"(iii) CLARIFICATION.—Notwithstanding clause (i), in the case of a rebate period and a covered outpatient drug that is a selected drug (as defined in section 1192(c)) during such rebate period, any reduction in price paid during the rebate period to the manufacturer for the drug by a wholesaler or retail community pharmacy described in subparagraph (A) by reason of application of part E of title XI shall be included in the average manufacturer price for the covered outpatient drug."

(4) FEHBP.—Section 8962 of title 5, United States Code, is amended by adding at the end the following:

"(p) A contract may not be made or a plan approved under this chapter with any carrier that has affirmatively elected, pursuant to section 1107 of the Social Security Act, not to participate in the Fair Price Negotiation Program established under section 1194 of such Act; as for any selected drug (as that term is defined in section 1192(c) of such Act)."
(5) **Option of Secretary of Veterans Affairs to Purchase Covered Drugs at Maximum Fair Prices.**—Section 8126 of title 38, United States Code, is amended—

(A) in subsection (a)(2), by inserting "subject to subsection (j)" after "may not exceed;"

(B) in subsection (d), in the matter preceding paragraph (1), by inserting "subject to subsection (j)" after "for the procurement of the drug"; and

(C) by adding at the end the following new subsection:

"(f)"

"(1) In the case of a covered drug that is a selected drug, for any year during the price applicability period for such drug, if the Secretary determines that the maximum fair price of such drug for such year is less than the price for such drug otherwise in effect pursuant to this section (including after application of any reduction under subsection (a)(2) and any discount under subsection (c)); at the option of the Secretary, in lieu of the maximum price (determined after application of the reduction under subsection (a)(2) and any discount under subsection (c), as applicable) that would be permitted to be charged during such year for such drug pursuant to this section without application of this subsection, the maximum price permitted to be charged during such year for such drug pursuant to this section shall be such maximum fair price for such drug and year.

"(2) For purposes of this subsection:

"(A) The term 'maximum fair price' means, with respect to a selected drug and year during the price applicability period for such drug, the maximum fair price (as defined in section 1191(c)(2) of the Social Security Act) for such drug and year.

"(B) The term 'negotiation-eligible drug' has the meaning given such term in section 1192(d)(1) of the Social Security Act.

"(C) The term 'price applicability period' has, with respect to a selected drug, the meaning given such term in section 1191(b)(2) of such Act.

"(D) The term 'selected drug' means, with respect to a year, a drug that is a selected drug under section 1192(c) of such Act for such year."

*Sec. 439002. Selected drug manufacturer excise tax imposed during noncompliance periods*

(a) IN GENERAL.—

Subchapter E of chapter 32 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:

"Sec. 4192. Selected drugs during noncompliance periods

(a) IN GENERAL.—There is hereby imposed on the sale by the manufacturer, producer, or importer of any selected drug during a day described in subsection (b) a tax in an amount such that its applicable percentage is equal to the ratio of—

"(4) such tax, divided by
"(2) the sum of such tax and the price for which so sold:

(b) Noncompliance Periods.—A day is described in this subsection with respect to a selected drug if it is a day during one of the following periods:

"(1) The period beginning on the June 16th immediately following the selected drug publication date and ending on the first date during which the manufacturer of the drug has in place an agreement described in subsection (a) of section 1193 of the Social Security Act with respect to such drug:

"(2) The period beginning on the April 1st immediately following the June 16th described in paragraph (1) and ending on the first date during which the manufacturer of the drug has agreed to a maximum fair price under such agreement:

"(3) In the case of a selected drug with respect to which the Secretary of Health and Human Services has specified a renegotiation period under such agreement, the period beginning on the first date after the last date of such renegotiation period and ending on the first date during which the manufacturer of the drug has agreed to a renegotiated maximum fair price under such agreement:

"(4) With respect to information that is required to be submitted to the Secretary of Health and Human Services under such agreement, the period beginning on the date on which such Secretary certifies that such information is overdue and ending on the date that such information is so submitted:

"(5) In the case of a selected drug with respect to which a payment is due under subsection (c) of such section 1193, the period beginning on the date on which the Secretary of Health and Human Services certifies that such payment is overdue and ending on the date that such payment is made in full:

"(e) Applicable Percentage.—For purposes of this section, the term ‘applicable percentage’ means—

"(1) in the case of sales of a selected drug during the first 90 days described in subsection (b) with respect to such drug, 65 percent;

"(2) in the case of sales of such drug during the 91st day through the 180th day described in subsection (b) with respect to such drug, 75 percent;

"(3) in the case of sales of such drug during the 181st day through the 270th day described in subsection (b) with respect to such drug, 85 percent; and

"(4) in the case of sales of such drug during any subsequent day, 95 percent;

(d) Selected Drug.—For purposes of this section—

"(1) In General.—The term ‘selected drug’ means any selected drug (within the meaning of section 1192 of the Social Security Act) which is manufactured or produced in the United States or entered into the United States for consumption, use, or warehousing:

"(2) United States.—The term ‘United States’ has the meaning given such term by section 4612(a)(4):

"(3) Coordination with Rules for Possessions of the United States.—Rules similar to the rules of paragraphs (2) and (4) of section 4432(e) shall apply for purposes of this section.
"(e) OTHER DEFINITIONS.— For purposes of this section, the terms 'selected drug publication date' and 'maximum fair price' have the meaning given such terms in section 1194 of the Social Security Act.

(f) ANTI-ABUSE RULE.— In the case of a sale which was timed for the purpose of avoiding the tax imposed by this section, the Secretary may treat such sale as occurring during a day described in subsection (b).

(b) NO REDUCTION FOR EXCISE TAX PAYMENTS.— Section 275 of the Internal Revenue Code of 1986 is amended by adding "or by section 4192" before the period at the end of subsection (a)(6).

(c) CONFORMING AMENDMENTS.—

(1) Section 4224(a) of the Internal Revenue Code of 1986 is amended by inserting "or 4192" after "section 4194";

(2) Section 6418(b)(2) of such Code is amended by inserting "or 4192" after "section 4194";

(d) CLERICAL AMENDMENTS.—

(1) The heading of subchapter E of chapter 32 of the Internal Revenue Code of 1986 is amended by striking "Medical devices" and inserting "Other medical products";

(2) The table of subchapters for chapter 32 of such Code is amended by striking the item relating to subchapter E and inserting the following new item:

"SUBCHAPTER E: OTHER MEDICAL PRODUCTS";

(3) The table of sections for subchapter E of chapter 32 of such Code is amended by adding at the end the following new item:

"Sec. 4192. Selected drugs during noncompliance periods."

(e) EFFECTIVE DATE.— The amendments made by this section shall apply to sales after the date of the enactment of this Act.

Sec. 439003. Fair Price Negotiation Implementation Fund

(a) IN GENERAL.— There is hereby established a Fair Price Negotiation Implementation Fund (referred to in this section as the "Fund"). The Secretary of Health and Human Services may obligate and expend amounts in the Fund to carry out this part in part 3 and 3 (and the amendments made by such parts).

(b) FUNDING.— There is authorized to be appropriated, and there is hereby appropriated, out of any monies in the Treasury not otherwise appropriated, to the Fund $3,000,000,000, to remain available until expended, of which—

(1) $600,000,000 shall become available on the date of the enactment of this Act;

(2) $600,000,000 shall become available on October 1, 2022;

(3) $600,000,000 shall become available on October 1, 2024;

(4) $600,000,000 shall become available on October 1, 2025; and
$600,000,000 shall become available on October 1, 2026.

(c) **SUPPLEMENT NOT SUBPLANT.**— Any amounts appropriated pursuant to this section shall be in addition to any other amounts otherwise appropriated pursuant to any other provision of law.

*Sec. 139101. Medicare part B rebate by manufacturers*

(a) **IN GENERAL.**— Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by adding at the end the following new subsection:

"(e) Rebate by manufacturers for single-source drugs with prices increasing faster than inflation.

(1) Requirements.

(A) Secretryal provision of information.— Not later than 6 months after the end of each calendar quarter beginning on or after July 1, 2023, the Secretary shall, for each part B rebateable drug, report to each manufacturer of such part B rebateable drug the following for such calendar quarter:

(i) Information on the total number of units of the billing and payment code described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter;

(ii) Information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter;

(iii) The rebate amount specified under such paragraph for such part B rebateable drug and calendar quarter.

(B) Manufacturer requirement.— For each calendar quarter beginning on or after July 1, 2023, the manufacturer of a part B rebateable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter.

(e) Part B rebateable drug defined.—

(A) In general.— In this subsection, the term ‘part B rebateable drug’ means a single-source drug or biological (as defined in subparagraph (D) of section 1847A(c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such section), payable (if such drug were furnished to an individual enrolled under this part under this part, except such term shall not include such a drug or biological—

(i) if the average total allowed charges under this part as determined by the Secretary for a year per individual that uses such a drug or biological, as determined by the Secretary, are less than, subject to subparagraph (B), $100; or

(ii)
"(ii) that is a vaccine described in subparagraph (A) or (B) of section 1864(a)(40);

"(B) INCREASE.— The dollar amount applied under subparagraph (A)(i)

"(i) for 2024, shall be the dollar amount specified under such subparagraph for 2023, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period ending with June of the previous year, and

"(ii) for a subsequent year, shall be the dollar amount specified in this clause (or clause (i)) for the previous year, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period ending with June of the previous year.

Any dollar amount specified under this subparagraph that is not a multiple of $10 shall be rounded to the nearest multiple of $10.

"(3) REBATE AMOUNT—

"(A) IN GENERAL.— For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraph (B) and paragraph (4), the amount equal to the product of—

"(i) the total number of units, as described in section 1847A(c)(1)(B), with respect to such drug during the calendar quarter; and

"(ii) the amount (if any) by which—

"(I) the payment amount under subparagraph (B) or (C) of section 1847A(b)(1), as applicable, for such part B rebatable drug during the calendar quarter, exceeds

"(II) the inflation-adjusted payment amount determined under subparagraph (G) for such part B rebatable drug during the calendar quarter.

"(B) EXCLUDED UNITS.— For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units with respect to a part B rebatable drug and calendar quarter units of such part B rebatable drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for the most recent rebate period.

"(C) DETERMINATION OF INFLATION-ADJUSTED PAYMENT AMOUNT.— The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is—

"(i) the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D));

increased by

"(ii) the percentage, by which the rebate period CPI-U (as defined in subparagraph (F)) for the calendar quarter exceeds the benchmark period CPI-U (as defined in subparagraph (E));
(D) Payment-Amount Benchmark Quarter.—The term "payment-amount benchmark quarter" means the calendar quarter beginning January 1, 2016.

(E) Benchmark Period CPI-U.—The term "benchmark period CPI-U" means the consumer-price index for all urban consumers (United States city average) for July 2015.

(F) Rebate Period CPI-U.—The term "rebate period CPI-U" means, with respect to a calendar quarter described in subparagraph (G), the greater of the benchmark period CPI-U and the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter.

(4) Special Treatment of Certain Drugs and Exemption.—

(A) Subsequently Approved Drugs.—Subject to subparagraph (B), in the case of a part B rebateable drug first approved or licensed by the Food and Drug Administration after July 1, 2015, clause (i) of paragraph (3)(C) shall be applied as if the term "payment-amount benchmark quarter" were defined under paragraph (3)(D) as the third full calendar quarter after the day on which the drug was first marketed and clause (ii) of paragraph (3)(C) shall be applied as if the term "benchmark period CPI-U" were defined under paragraph (3)(E) as if the reference to "July 2015" under such paragraph were a reference to the first month of the first full calendar quarter after the day on which the drug was first marketed.

(B) Timeline for Provision of Rebates for Subsequently Approved Drugs.—In the case of a part B rebateable drug first approved or licensed by the Food and Drug Administration after July 1, 2015, paragraph (1)(B) shall be applied as if the reference to "July 1, 2023" under such paragraph were a reference to the later of the 6th full calendar quarter after the day on which the drug was first marketed or July 1, 2023.

(C) Exemption for Shortages.—The Secretary may reduce or waive the rebate amount under paragraph (4)(B) with respect to a part B rebateable drug that is described as currently in shortage on the shortage list in effect under section 566E of the Federal Food, Drug, and Cosmetic Act or in the case of other exigent circumstances, as determined by the Secretary.

(D) Selected Drugs.—In the case of a part B rebateable drug that is a selected drug (as defined in section 1402(e)) for a price-applicability period (as defined in section 1494(b)(2))—

(i) for calendar quarters during such period for which a maximum fair price (as defined in section 1494(e)(2)) for such drug has been determined and is applied under part E of title XI, the rebate amount under paragraph (4)(B) shall be waived; and

(ii) in the case such drug is determined (pursuant to such section 1402(e)) to no longer be a selected drug, for each applicable year beginning after the price-applicability period with respect to such drug, clause (i) of paragraph (3)(C) shall be applied as if the term "payment-amount benchmark quarter" were
defined under paragraph (3)(D) as the calendar quarter beginning January 1 of the last year beginning during such price applicability period with respect to such selected drug and clause (ii) of paragraph (3)(G) shall be applied as if the term "benchmark period: CPI-U" were defined under paragraph (3)(E) as if the reference to "July 2015" under such paragraph were a reference to the July of the year preceding such last year.

"(5) APPLICATION TO BENEFICIARY COINSURANCE.— In the case of a part B rebatable drug, if the payment amount under this part for a quarter exceeds the inflation-adjusted payment for such quarter—

(A) in computing the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished, the computation of such coinsurance shall be based on the inflation-adjusted payment amount determined under paragraph (3)(C) for such part B rebatable drug; and

(B) the amount of such coinsurance is equal to 20 percent of such inflation-adjusted payment amount so determined;

"(6) REBATE DEPOSITS.— Amounts paid as rebates under paragraph (1)(B) shall be deposited into the Federal Supplementary Medical Insurance Trust Fund established under section 11411.

"(7) CIVIL MONEY PENALTY.— If a manufacturer of a part B rebatable drug has failed to comply with the requirements under paragraph (1)(B) for such drug for a calendar quarter, the manufacturer shall be subject to, in accordance with a process established by the Secretary pursuant to regulations, a civil money penalty in an amount equal to at least 125 percent of the amount specified in paragraph (3) for such drug for such calendar quarter. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a):

"(8) APPLICATION TO MULTIPLE SOURCE DRUGS.— The Secretary may, pursuant to rulemaking, apply the provisions of this subsection to multiple source drugs (as defined in section 1847A(c)(6)(G)), including, for purposes of determining the rebate amount under paragraph (3), by calculating manufacturer-specific average sales prices for the benchmark period and the rebate period."

(b) AMOUNTS PAYABLE; COST-SHARING.— Section 1833 of the Social Security Act (42 U.S.C. 1395i) is amended—

(1) in subsection (a)—

(A) in paragraph (1)—

(i) in subparagraph (G), by inserting ", subject to subsection (i)(9)," after "the amounts paid;

(ii) in subparagraph (G), by striking "with respect to" and inserting "subject to paragraph (DD) with respect to";

(iii) by striking "and (DD)" and inserting "(EE),"; and
(iv) by inserting before the semicolon at the end the following: ";, and (EE) with respect to a part B rebateable drug (as defined in paragraph (2) of section 4834(z)) for which the payment amount for a calendar quarter under paragraph (3)(A)(ii)(I) of such section for such quarter exceeds the inflation-adjusted payment under paragraph (3)(A)(ii)(II) of such section for such quarter, the amount paid shall be the difference between (I) the payment amount under paragraph (3)(A)(ii)(I) of such section for such drug, and (II) 20 percent of the inflation-adjusted payment amount under paragraph (3)(A)(ii)(II) of such section for such drug; and

(B) by adding at the end of the flush left matter following paragraph (9), the following: For purposes of applying paragraph (1)(EE), subsections (i)(2) and (i)(8) (F), and section 1834(z)(5), the Secretary shall make such estimates and use such data as the Secretary determines appropriate, and may do so by program instruction or otherwise:

(2) in subsection (i), by adding at the end the following new paragraph:

"In the case of a part B rebateable drug (as defined in paragraph (2) of section 4834(z)) for which payment under this subsection is not packaged into a payment for a covered OPD service (as defined in subsection (l)(4)(B)) (or group of services) furnished on or after July 1, 2023, under the system under this subsection, in lieu of calculation of coinsurance and the amount of payment otherwise applicable under this subsection, the provisions of section 1834(z)(5), paragraph (1)(EE) of subsection (a), and the flush left matter following paragraph (9) of section 1834(z) and subsection (a), shall, as determined appropriate by the Secretary, apply under this subsection in the same manner as such provisions of section 1834(z) and subsection (a) apply under such section and subsection:";

(3) in subsection (1)(6), by adding at the end the following new subparagraph:

"Part B Rebateable Drugs.—In the case of a part B rebateable drug (as defined in paragraph (2) of section 1834(z)) for which payment under this part is not packaged into a payment for a service furnished on or after July 1, 2023, under the system under this subsection, in lieu of calculation of coinsurance and the amount of payment otherwise applicable under this subsection, the provisions of section 1834(z)(5), paragraph (1)(EE) of subsection (a), and the flush left matter following paragraph (9) of subsection (a), shall, as determined appropriate by the Secretary, apply under this subsection in the same manner as such provisions of section 1834(z) and subsection (a) apply under such section and subsection:";

(c) Conforming Amendments:—

(1) To Part B ASP calculation.—Section 1847A(o)(3) of the Social Security Act (42 U.S.C. 1395w–3a(c)(3)) is amended by inserting "or section 1834(z)" after "section 4927;)"

(2) Excluding parts B drug inflation rebate from best price.—Section 4927A(e)(1)(G)(iii)(I) of the Social Security Act (42 U.S.C. 1395w–3a(c)(1)(G)(iii)(I)) is amended by inserting "or section 1834(z)" after "this section":

billcompare.senate.gov

1432/1449
(3) Coordination with Medicaid rebate information disclosure.—Section 4927(b)(3)(D)(ii) of the Social Security Act (42 U.S.C. 1396r-8(b)(3)(D)(ii)) is amended by striking "to carry out section 1847B" and inserting "to carry out section 1847B or section 1834(2)"

*Sec. 139102. Medicare Part D rebate by manufacturers*

(a) In general.—

Part D of title XVIII of the Social Security Act is amended by inserting after section 1860D-44A (42 U.S.C. 1395w-114e) the following new section:

"Sec. 1860D-14B. Manufacturer rebate for certain drugs with prices increasing faster than inflation"

(1) Secretarial provision of information.—Not later than 9 months after the end of each applicable year (as defined in subsection (g)(7)), the Secretary shall, for each Part D rebatable drug, report to each manufacturer of such Part D rebatable drug the following for such year:

(A) Information on the amount (if any) of the excess average manufacturer price increase described in subsection (b)(4)(B) for each dosage form and strength with respect to such drug and year.

(B) The rebate amount specified under subsection (b) for each dosage form and strength with respect to such drug and year.

(2) Manufacturer requirements.—For each applicable year, the manufacturer of a Part D rebatable drug, for each dosage form and strength with respect to such drug, not later than 30 days after the date of receipt from the Secretary of the information described in paragraph (1) for such year, shall provide to the Secretary a rebate that is equal to the amount specified in subsection (b) for such dosage form and strength with respect to such drug for such year.

(1) Rebate amount.—

(A) Calculation.—For purposes of this section, the amount specified in this subsection for a dosage form and strength with respect to a Part D rebatable drug and applicable year is, subject to subparagraph (B) of this paragraph and subparagraphs (B) and (C) of paragraph (5), the amount equal to the product of—

(i) the total number of units that are used to calculate the average manufacturer price of such dosage form and strength with respect to such Part D rebatable drug, as reported by the manufacturer of such drug under section 1927 for each recent rebate period under such section, with respect to such year, under such section for which such information is available; and

(ii) the amount (if any) by which—

the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such Part D
rebateable drug for the year; exceeds

"(ii) the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebateable drug for the year.

"(B) EXCLUDED UNITS.—For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebateable drug and the most recent rebate period under section 1927, with respect to an applicable year, for which such information is available, units of each dosage form and strength of such part D rebateable drug, for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for such rebate period;

"(2) DETERMINATION OF ANNUAL MANUFACTURER PRICE.—The annual manufacturer price determined under this paragraph for a dosage form and strength, with respect to a part D rebateable drug and an applicable year, is the sum of the products of—

"(A) the average manufacturer price (as defined in subsection (g)(6)) of such dosage form and strength, as calculated for a unit of such drug, with respect to each of the calendar quarters of such year; and

"(B) the ratio of—

(ii) the total number of units of such dosage form and strength reported for the purpose of calculating average manufacturer price under section 1927 during each such calendar quarter of such year; to

(iii) the total number of units of such dosage form and strength reported for the purpose of calculating average manufacturer price under section 1927 during such year, as determined by the Secretary;

"(3) DETERMINATION OF INFLATION-ADJUSTED PAYMENT AMOUNT.—The inflation-adjusted payment amount determined under this paragraph for a dosage form and strength with respect to a part D rebateable drug for an applicable year, subject to subparagraphs (A) and (D) of paragraph (5), is—

"(A) the benchmark year manufacturer price determined under paragraph (4) for such dosage form and strength with respect to such drug and year, increased by

"(B) the percentage by which the applicable year CPI-U (as defined in subsection (g)(5)) for the year exceeds the benchmark period CPI-U (as defined in subsection (g)(4));

"(4) DETERMINATION OF BENCHMARK YEAR MANUFACTURER PRICE.—The benchmark year manufacturer price determined under this paragraph for a dosage form and strength, with respect to a part D rebateable drug and an applicable year, is the sum of the products of—

"(A) the average manufacturer price (as defined in subsection (g)(6)) of such dosage form and strength, as calculated for a unit of such drug, with respect to each of the calendar quarters of the payment amount benchmark year (as defined in subsection (g)(3)); and
"(B) the ratio of—

"(i) the total number of units of such dosage form and strength dispensed during each such calendar quarter of such payment amount benchmark year; to

"(ii) the total number of units of such dosage form and strength dispensed during such payment amount benchmark year.

"(E) SPECIAL TREATMENT OF CERTAIN DRUGS AND EXEMPTION—

"(A) SUBSEQUENTLY APPROVED DRUGS.—In the case of a part D rebatable drug first approved or licensed by the Food and Drug Administration after January 1, 2016, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term 'payment amount benchmark year' were defined under subsection (g)(3) as the first calendar year beginning after the day on which the drug was first marketed by any manufacturer and subparagraph (B) of paragraph (3) shall be applied as if the term 'benchmark period GPI-U' were defined under subsection (g)(1) as if the reference to 'January 2016' under such subsection were a reference to 'January of the first year beginning after the date on which the drug was first marketed by any manufacturer';

"(B) EXEMPTION FOR SHORTAGES.—The Secretary may reduce or waive the rebate under paragraph (4) with respect to a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 505E of the Federal Food, Drug, and Cosmetic Act or in the case of other exigent circumstances, as determined by the Secretary;

"(C) TREATMENT OF NEW FORMULATIONS—

"(i) IN GENERAL.—In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the amount specified in this subsection with respect to such part D rebatable drug and an applicable year with consideration of the original part D rebatable drug;

"(ii) LINE EXTENSION DEFINED.—In this subparagraph, the term 'line extension' means, with respect to a part D rebatable drug, a new formulation of the drug, such as an extended release formulation, but does not include an abuse-deterrent formulation of the drug (as determined by the Secretary), regardless of whether such abuse-deterrent formulation is an extended release formulation;

"(D) SELECTED DRUGS.—In the case of a part D rebatable drug that is a selected drug (as defined in section 1192(e)) for a price applicability period (as defined in section 1191(b)(2))—

"(i) for plan years during such period for which a maximum fair price (as defined in section 1191(c)(2)) for such drug has been determined and is applied under part E of title XI, the rebate under subsection (a)(1)(B) shall be waived; and

"(ii) in the case such drug is determined (pursuant to such section 1192(e)) to no longer be a selected drug; for each applicable year beginning after the price applicability period with respect to such drug, subparagraphs (A) and (B) of
paragraph (4) shall be applied as if the term "payment amount" were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph (B) of paragraph (3) shall be applied as if the term "benchmark period - CPI-U" were defined under subsection (g)(4) as if the reference to "January 2016" under such subsection were a reference to January of the last year beginning during such price applicability period with respect to such drug:

"(e) REBATE DEPOSITS.— Amounts paid as rebates under subsection (b) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1841:

"(d) INFORMATION.— For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A):

"(e) CIVIL MONEY PENALTY.— If a manufacturer of a part D rebateable drug has failed to comply with the requirement under subsection (b)(1)(B) with respect to such drug for an applicable year, the manufacturer shall be subject to, in accordance with a process established by the Secretary pursuant to regulations, a civil money penalty in an amount equal to 425 percent of the amount specified in subsection (b) for such drug for such year. The provisions of section 1428A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1428A(a):

"(f) JUDICIAL REVIEW.— There shall be no judicial review of the following:

"(1) The determination of units under this section:

"(2) The determination of whether a drug is a part D rebateable drug under this section:

"(3) The calculation of the rebate amount under this section:

"(g) DEFINITIONS.— In this section:

"(4) PART D REBATEABLE DRUG DEFINED:

"(A) IN GENERAL.— The term "part D rebateable drug" means a drug or biological that would (without application of this section) be a covered part D drug, except such term shall, with respect to an applicable year, not include such a drug or biological if the average annual total cost under this part for such year per individual who uses such a drug or biological, as determined by the Secretary, is less than, subject to subparagraph (B), $100, as determined by the Secretary using the most recent data available or, if data is not available, as estimated by the Secretary:

"(B) INCREASE.— The dollar amount applied under subparagraph (A) shall be the dollar amount specified under such subparagraph for 2023, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with January of 2023, and
"(ii) for a subsequent year, shall be the dollar amount specified in this subparagraph for the previous year, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with January of the previous year.

Any dollar amount specified under this subparagraph that is not a multiple of $10 shall be rounded to the nearest multiple of $10:

"(2) UNIT DEFINED.—The term 'unit' means, with respect to a part D rebatable drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug, including data reported under section 1927:

"(3) PAYMENT AMOUNT BENCHMARK YEAR.—The term 'payment amount benchmark year' means the year beginning January 1, 2016:

"(4) BENCHMARK PERIOD CPI-U.—The term 'benchmark period CPI-U' means the consumer price index for all urban consumers (United States city average) for January 2016.

"(5) APPLICABLE YEAR CPI-U.—The term 'applicable year CPI-U' means, with respect to an applicable year, the consumer price index for all urban consumers (United States city average) for January of such year.

"(6) AVERAGE MANUFACTURER PRICE.—The term 'average manufacturer price' has the meaning, with respect to a part D rebatable drug of a manufacturer, given such term in section 1927(c)(4)(B), with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1927.

"(7) APPLICABLE YEAR.—The term 'applicable year' means a year beginning with 2023.

(b) CONFORMING AMENDMENTS:

(1) TO PART D ASP CALCULATION.—Section 1347A(e)(3) of the Social Security Act (42 U.S.C. 1395w–2(a)(3)), as amended by section 139101(e)(1), is further amended by striking "section 1927 or section 1834(z)") and inserting "section 1927, section 1834(z), or section 1860D–14B":

(2) EXCLUDING PART D DRUG INFLATION REBATE FROM BEST PRICE.—Section 1927(c)(1)(B)(i)(iv) of the Social Security Act (42 U.S.C. 1395w–2(b)(3)(D)(i)(v)), as amended by section 139101(e)(2), is further amended by striking "or section 1834(z)" and inserting "section 1834(z), or section 1860D–14B":

(3) COORDINATION WITH MEDICAID REBATE INFORMATION DISCLOSURE.—Section 1927(b)(3)(D)(i) of the Social Security Act (42 U.S.C. 1395w–2(b)(3)(D)(i)), as amended by section 139101(e)(3), is further amended by striking "or section 1834(z)" and inserting "section 1834(z), or section 1860D–14B":

Sec. 439204.—Medicare part D benefit-redesign

(a) BENEFIT STRUCTURE REDESPIGN.—Section 1860D–2(b) of the Social Security Act (42 U.S.C. 1395w–102(b)) is amended—

(1) in paragraph (2)—
(A) in subparagraph (A), in the matter preceding clause (i), by inserting "for a year preceding 2024 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4) for 2024 and each subsequent year" after "paragraph (3)";

(B) in subparagraph (C)—
   (i) in clause (i), in the matter preceding subclause (I), by inserting "for a year preceding 2024," after "paragraph (4),"; and
   (ii) in clause (ii)(III), by striking "and each subsequent year" and inserting "through 2023";

(C) in subparagraph (D)—
   (i) in clause (i)—
      (I) in the matter preceding subclause (I), by inserting "for a year preceding 2024," after "paragraph (4),"; and
      (II) in subclause (I)(bb), by striking "a year after 2018" and inserting "each of years 2018 through 2023"; and
   (ii) in clause (ii)(V), by striking "2019 and each subsequent year" and inserting "each of years 2019 through 2023";

(2) in paragraph (3)(A)—
   (A) in the matter preceding clause (i), by inserting "for a year preceding 2024," after "and (4),"; and
   (B) in clause (ii), by striking "for each subsequent year" and inserting "for each of years 2007 through 2023"; and

(3) in paragraph (4)—
   (A) in subparagraph (A)—
      (i) in clause (i)—
         (I) by redesignating subclauses (I) and (ii) as items (aa) and (bb); respectively, and moving the margin of each such redesignated item 2 ems to the right;
         (II) in the matter preceding item (aa), as redesignated by subclause (I), by striking "is equal to the greater of—" and inserting "is equal to—";
         (III) by striking the period at the end of item (bb), as redesignated by subclause (I), and inserting "; and"; and
         (IV) by adding at the end the following:
            "(II) for 2024 and each succeeding year, $9,000; and
            (iii) in clause (ii), by striking "clause (i)(I)" and inserting "clause (i)(I)(aa)";

   (B) in subparagraph (B)—
      (i) in clause (i)—
         (I) in subclause (V), by striking "or" at the end;
(II) in subclause (VI)—

(aa) by striking "for a subsequent year" and inserting "for each of years 2024 through 2026"; and

(bb) by striking the period at the end and inserting a semicolon;

and

(III) by adding at the end the following new subclauses:

"(VII) for 2024, is equal to $2,000; or

"(VIII) for a subsequent year, is equal to the amount specified in this subparagraph for the previous year, increased by the annual percentage increase described in paragraph (G) for the year involved;";

and

(ii) in clause (ii), by striking "clause (i)/(ii)" and inserting "clause (i)";

(G) in subparagraph (G)(i), by striking "and for amounts" and inserting "and, for a year preceding 2024, for amounts"; and

(D) in subparagraph (E), by striking "In applying" and inserting "For each of years 2021 through 2023, in applying";

(b) DECREASING REINSURANCE PAYMENT AMOUNT.—Section 1860D–15(b)(1) of the Social Security Act (42 U.S.C. 1395w–445(b)(1)) is amended by inserting after "80 percent" the following: "(or, with respect to a coverage year after 2023, 20 percent)".

(c) MANUFACTURER DISCOUNT PROGRAM.—

(1) IN GENERAL.—Part D of title XVIII of the Social Security Act (42 U.S.C. 1395w–401 et seq.), as amended by section 139162, is further amended by inserting after section 1860D–14B the following new section:

"Sec. 1860D–14C. Manufacturer discount program

"(a) ESTABLISHMENT.—The Secretary shall establish a manufacturer discount program (in this section referred to as the 'program'). Under the program, the Secretary shall enter into agreements described in subsection (b) with manufacturers and provide for the performance of the duties described in subsection (c). The Secretary shall establish a model agreement for use under the program by not later than January 1, 2023, in consultation with manufacturers, and allow for comment on such model agreement.

"(b) TERMS OF AGREEMENT.—

"(1) IN GENERAL.—

"(A) AGREEMENT.—An agreement under this section shall require the manufacturer to provide applicable beneficiaries access to discounted prices for applicable drugs of the manufacturer that are dispensed on or after January 1, 2024.

"(B) PROVISION OF DISCOUNTED PRICES AT THE POINT-OF-SALE.—The discounted prices described in subparagraph (A) shall be provided to the
applicable beneficiary at the pharmacy or by the mail-order service at the point-of-sale of an applicable drug.

"(C) TIMING OF AGREEMENT.—

"(i) Special Rule for 2024.—In order for an agreement with a manufacturer to be in effect under this section with respect to the period beginning on January 1, 2024, and ending on December 31, 2024, the manufacturer shall enter into such agreement not later than 30 days after the date of the establishment of a model agreement under subsection (a):

"(ii) 2025 and Subsequent Years.—In order for an agreement with a manufacturer to be in effect under this section with respect to plan year 2025 or a subsequent plan year, the manufacturer shall enter into such agreement (or such agreement shall be renewed under paragraph (4)(A)) not later than January 30 of the preceding year.

"(2) Provision of Appropriate Data.— Each manufacturer with an agreement in effect under this section shall collect and have available appropriate data, as determined by the Secretary, to ensure that it can demonstrate to the Secretary compliance with the requirements under the program.

"(3) Compliance With Requirements for Administration of Program.— Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under subsection (d)(3), as applicable, for purposes of administering the program, including any determination under subparagraph (A) of subsection (c)(1) or procedures established under such subsection (c)(1):

"(4) Length of Agreement.—

"(A) In General.—An agreement under this section shall be effective for an initial period of not less than 12 months and shall be automatically renewed for a period of not less than 1 year unless terminated under subparagraph (B):

"(B) Termination.—

"(i) By the Secretary.—The Secretary may provide for termination of an agreement under this section for a knowing and willful violation of the requirements of the agreement or other good cause shown. Such termination shall not be effective earlier than 30 days after the date of notice to the manufacturer of such termination. The Secretary shall provide, upon request, a manufacturer with a hearing concerning such a termination, and such hearing shall take place prior to the effective date of the termination with sufficient time for such effective date to be repealed if the Secretary determines appropriate:

"(ii) By a Manufacturer.—A manufacturer may terminate an agreement under this section for any reason. Any such termination shall be effective, with respect to a plan year—

"(i) if the termination occurs before January 30 of a plan year, as of the day after the end of the plan year; and
"(ii) if the termination occurs on or after January 30 of a plan year, as of the day after the end of the succeeding plan year.

"(iii) Effectiveness of Termination.— Any termination under this subparagraph shall not affect discounts for applicable drugs of the manufacturer that are due under the agreement before the effective date of its termination.

"(iv) Notice to Third Party.— The Secretary shall provide notice of such termination to a third party with a contract under subsection (d)(3) within not less than 30 days before the effective date of such termination.

"(c) Duties Described.— The duties described in this subsection are the following:

"(1) Administration of Program.— Administering the program, including—

"(A) the determination of the amount of the discounted price of an applicable drug of a manufacturer;

"(B) the establishment of procedures under which discounted prices are provided to applicable beneficiaries at pharmacies or by mail order service at the point of sale of an applicable drug;

"(C) the establishment of procedures to ensure that, not later than the applicable number of calendar days after the dispensing of an applicable drug by a pharmacy or mail order service, the pharmacy or mail order service is reimbursed for an amount equal to the difference between—

"(i) the negotiated price of the applicable drug; and

"(ii) the discounted price of the applicable drug;

"(D) the establishment of procedures to ensure that the discounted price for an applicable drug under this section is applied before any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of applicable beneficiaries as the Secretary may specify; and

"(E) providing a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, applicable beneficiaries, and the third party with a contract under subsection (d)(3):

"(2) Monitoring Compliance.—

"(A) In General.— The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under this section:

"(B) Notification.— If a third party with a contract under subsection (d)(3) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such noncompliance for appropriate enforcement under subsection (e):

"(3) Collection of Data from Prescription Drug Plans and MA-PD Plans:— The Secretary may collect appropriate data from prescription drug plans and MA-PE plans in a timeframe that allows for discounted prices to be provided for applicable drugs under this section:
(d) Administration.—

(1) In General.—Subject to paragraph (2), the Secretary shall provide for the implementation of this section, including the performance of the duties described in subsection (c).

(2) Limitation.—In providing for the implementation of this section, the Secretary shall not receive or distribute any funds of a manufacturer under the program:

(3) Contract with Third Parties.—The Secretary shall enter into a contract with one or more third parties to administer the requirements established by the Secretary in order to carry out this section. At a minimum, the contract with a third party under the preceding sentence shall require that the third party—

(A) receive and transmit information between the Secretary, manufacturers, and other individuals or entities the Secretary determines appropriate;

(B) receive, distribute, or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to meet the obligations of manufacturers under agreements under this section;

(C) provide adequate and timely information to manufacturers, consistent with the agreement with the manufacturer under this section, as necessary for the manufacturer to fulfill its obligations under this section; and

(D) permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program.

(4) Performance Requirements.—The Secretary shall establish performance requirements for a third party with a contract under paragraph (3) and safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this section.

(5) Implementation.—The Secretary may implement the program under this section by program instruction or otherwise:

(6) Administration.—Chapter 35 of title 44, United States Code, shall not apply to the program under this section.

(e) Enforcement.—

(1) Audits.—Each manufacturer with an agreement in effect under this section shall be subject to periodic audit by the Secretary:

(A) In General.—The Secretary may impose a civil money penalty on a manufacturer that fails to provide applicable beneficiaries discounts for applicable drugs of the manufacturer in accordance with such agreement for each such failure in an amount the Secretary determines is equal to the sum of

(I) the amount that the manufacturer would have paid with respect to such discounts under the agreement, which will then be used to pay the
discounts which the manufacturer had failed to provide; and

(ii) 25 percent of such amount.

(B) APPLICATION. — The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).

(f) CLARIFICATION REGARDING AVAILABILITY OF OTHER COVERED PART-D DRUGS. — Nothing in this section shall prevent an applicable beneficiary from purchasing a covered part-D drug that is not an applicable drug (including a generic drug or a drug that is not on the formulary of the prescription drug plan or MA-PD plan that the applicable beneficiary is enrolled in):

(g) DEFINITIONS. — In this section:

(1) APPLICABLE BENEFICIARY. — The term "applicable beneficiary" means an individual who, on the date of dispensing a covered part-D drug—

(A) is enrolled in a prescription drug plan or an MA-PD plan;

(B) is not enrolled in a qualified retiree prescription drug plan; and

(C) has incurred costs, as determined in accordance with section 1860D-2(b)(4)(C), for covered part-D drugs in the year that exceed the annual deductible with respect to such individual for such year, as specified in section 1860D-2(b)(1), section 1860D-14(a)(1)(A), section 1860D-14(a)(2)(B), as applicable;

(2) APPLICABLE DRUG. — The term "applicable drug," with respect to an applicable beneficiary—

(A) means a covered part-D drug—

(i) approved under a new drug application under section 505(e) of the Federal Food, Drug, and Cosmetic Act or, in the case of a biologic product, licensed under section 351 of the Public Health Service Act; and

(ii)

(I) if the PDP sponsor of the prescription drug plan or the MA organization offering the MA-PD plan uses a formulary, which is on the formulary of the prescription drug plan or MA-PD plan that the applicable beneficiary is enrolled in;

(II) if the PDP sponsor of the prescription drug plan or the MA organization offering the MA-PD plan does not use a formulary, for which benefits are available under the prescription drug plan or MA-PD plan that the applicable beneficiary is enrolled in; or

(III) is provided through an exception or appeal; and

(B) does not include a selected drug (as defined in section 1192(c)(1)) during a price applicability period (as defined in section 1191(b)(2)) with respect to such drug.
"(3) Applicable Number of Calendar Days.—The term "applicable number of calendar days" means—

(A) with respect to claims for reimbursement submitted electronically, 14 days; and

(B) with respect to claims for reimbursement submitted otherwise, 30 days.

(4) Discounted Price.—

(A) In General.—The term "discounted price" means, with respect to an applicable drug of a manufacturer dispensed during a year to an applicable beneficiary—

(i) who has not incurred costs, as determined in accordance with section 1860D-2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D-2(b)(4)(B)(i) for the year, 95 percent of the negotiated price of such drug; and

(ii) who has incurred such costs, as so determined, in the year that are equal to or exceed such threshold for the year, 70 percent of the negotiated price of such drug.

(B) Clarification.—Nothing in this section shall be construed as affecting the responsibility of an applicable beneficiary for payment of a dispensing fee for an applicable drug.

(G) Special Case for Certain Claims.—

(i) Claims Spanning Deductible.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall below the annual deductible specified in section 1860D-2(b)(1) for the year, the manufacturer of the applicable drug shall provide the discounted price under this section on only the portion of the negotiated price of the applicable drug that falls above such annual deductible.

(ii) Claims Spanning Out-of-Pocket Threshold.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall entirely below or entirely above the annual out-of-pocket threshold specified in section 1860D-2(b)(4)(B)(i) for the year, the manufacturer of the applicable drug shall provide the discounted price—

(i) in accordance with subparagraph (A)(i) on the portion of the negotiated price of the applicable drug that falls below such threshold; and

(ii) in accordance with subparagraph (A)(ii) on the portion of such price of such drug that falls at or above such threshold.

(F) Manufacturer.—The term "manufacturer" means any entity which is engaged in the production, preparation, propagation, compounding, conversion, or
processing—of—prescription—drug—products, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis; or by a combination of extraction and chemical synthesis. Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law.

"(6) NEGOTIATED PRICE.—The term "negotiated price" has the meaning given such term in section 423.100 of title 42, Code of Federal Regulations (or any successor regulation), except that, with respect to an applicable drug, such negotiated price shall not include any dispensing fee for the applicable drug.

"(7) QUALIFIED RETIREE PRESCRIPTION DRUG PLAN.—The term "qualified retiree prescription drug plan" has the meaning given such term in section 1860D–22(e)(2).

(2) SUNSET OF MEDICARE COVERAGE GAP DISCOUNT PROGRAM.—Section 1860B–44A of the Social Security Act (42 U.S.C. 1395–114) is amended—

(A) in subsection (a), in the first sentence, by striking "The Secretary" and inserting "Subject to subsection (h), the Secretary"; and

(B) by adding at the end the following new subsection:

"(h) SUNSET OF PROGRAM.—

"(1) IN GENERAL.—The program shall not apply with respect to applicable drugs dispensed on or after January 1, 2024, and, subject to paragraph (2), agreements under this section shall be terminated as of such date.

"(2) CONTINUED APPLICATION FOR APPLICABLE DRUGS DISPENSED PRIOR TO SUNSET.—The provisions of this section (including all responsibilities and duties) shall continue to apply after January 1, 2024, with respect to applicable drugs dispensed prior to such date."

(3) INCLUSION OF ACTUARIAL VALUE OF MANUFACTURER DISCOUNTS IN BIDS.—Section 4860D–11 of the Social Security Act (42 U.S.C. 1395w–111) is amended—

(A) in subsection (b)(2)(G)(i)—

(i) by striking "assumptions regarding the reinsurance" and inserting "assumptions regarding—

"(i) the reinsurance", and

(ii) by adding at the end the following:

"(ii) for 2024 and each subsequent year, the manufacturer discounts provided under section 1860D–44B (subtracted from the actuarial value to produce such bid); and"

(B) in subsection (c)(4)(C)—

(i) by striking "an actuarial valuation of the reinsurance" and inserting "an actuarial valuation of—

"(i) the reinsurance", and

(ii) in clause (i), as inserted by clause (i) of this subparagraph, by adding "and" at the end, and
(iii) by adding at the end the following:

"(ii) for 2024 and each subsequent year, the manufacturer discounts provided under section 1860D-14C.";

(d) CONFORMING AMENDMENTS—

(1) Section 1860D-2 of the Social Security Act (42 U.S.C. 1395w-102) is amended—

(A) in subsection (a)(2)(A)(i)(I), by striking "", or an increase in the initial", and inserting "or, for a year preceding 2024, an increase in the initial";

(B) in subsection (c)(1)(C)—

(i) in the subparagraph heading, by striking "at initial coverage limit"; and

(ii) by inserting "for a year preceding 2024, or the annual out-of-pocket threshold specified in subsection (b)(4)(B) for the year for 2024 and each subsequent year after "subsection (b)(3) for the year" each place it appears; and

(G) in subsection (d)(1)(A), by striking "or an initial" and inserting "or, for a year preceding 2024; an initial";

(2) Section 1860D-4(a)(4)(B)(i) of the Social Security Act (42 U.S.C. 1395w-104(a)(4)(B)(i)) is amended by striking "the initial" and inserting "for a year preceding 2024, the initial";

(3) Section 1860D-14(a) of the Social Security Act (42 U.S.C. 1395w-114(a)) is amended—

(A) in paragraph (1)—

(i) in subparagraph (C), by striking "The continuation" and inserting "For a year preceding 2024, the continuation";


(iii) in subparagraph (E), by striking "The elimination" and inserting "For a year preceding 2024, the elimination"; and

(B) in paragraph (2)—

(i) in subparagraph (C), by striking "The continuation" and inserting "For a year preceding 2024, the continuation"; and


(A) by striking "the value of any discount" and inserting the following:

the value of—
"(i) for years prior to 2024, any discount;\n
(B) in clause (i), as inserted by subparagraph (A) of this paragraph, by striking the period at the end and inserting"," and "; and

(C) by adding at the end the following new clause:

"(ii) for 2024 and each subsequent year, any discount provided pursuant to section 1860D-14C.;"

(6) Section 1860D-41(a)(6) of the Social Security Act (42 U.S.C. 1395w-151(a)(6)) is amended—

(A) by inserting "for a year before 2024" after "1860D-2(b)(3)"; and

(B) by inserting "for such year" before the period.

(7) Section 1860D-43 of the Social Security Act (42 U.S.C. 1395w-153) is amended

(A) in subsection (a)—

(i) by striking paragraph (1) and inserting the following:

"(1) participate in—

"(A) for 2011 through 2023, the Medicare coverage gap discount program under section 1860D-14A; and

"(B) for 2024 and each subsequent year, the manufacturer discount program under section 1860D-14C;"

(ii) by striking paragraph (2) and inserting the following:

"(2) have entered into and have in effect—

"(A) for 2011 through 2023, an agreement described in subsection (b) of section 1860D-14A with the Secretary; and

"(B) for 2024 and each subsequent year, an agreement described in subsection (b) of section 1860D-14C with the Secretary; and"

(iii) by striking paragraph (3) and inserting the following:

"(3) have entered into and have in effect, under terms and conditions specified by the Secretary—

"(A) for 2011 through 2023, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of section 1860D-14A; and

"(B) for 2024 and each subsequent year, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of section 1860D-14C.;"

(B) by striking subsection (b) and inserting the following:

"(b) Effectiveness—Paragraphs (1)(A), (2)(A), and (3)(A) of subsection (a) shall apply to covered part D drugs dispensed under this part on or after January 1, 2011; and before January 1, 2024, and paragraphs (1)(B), (2)(B), and (3)(B) of such
subsection shall apply to covered part D drugs dispensed under this part on or after January 1, 2024."

(8) Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) is amended—

(A) in subsection (e)(1)(C)(i)(V), by inserting before the period at the end the following: "or under the manufacturer discount program under section 1860D-14G;"

(B) in subsection (k)(1)(B)(i)(V) by inserting before the period at the end the following: "or under section 1860D-14G;"

(e) EFFECTIVE DATE.—The amendments made by this section shall apply with respect to plan year 2024 and subsequent plan years:

* Sec. 139292. Allowing certain enrollees of prescription drug plans and MA-PD plans under Medicare program to spread out cost-sharing under certain circumstances

Section 1860D-2(b)(2) of the Social Security Act (42 U.S.C. 1395w-102(b)(2)), as amended by section 139292, is further amended—

(1) in subparagraph (A), by striking "Subject to subparagraphs (C) and (D)" and inserting "Subject to subparagraphs (C), (D), and (E)"; and

(2) by adding at the end the following new subparagraph:

"(E) ENROLLEE OPTION REGARDING SPREADING COST-SHARING.—The Secretary shall establish by regulation a process under which, with respect to plan year 2024 and subsequent plan years, a prescription drug plan or an MA-PD plan shall, in the case of a part D eligible individual enrolled with such plan for such plan year who is not a subsidy eligible individual (as defined in section 1860D-14(e)(3)) and with respect to whom the plan projects that the dispensing of the first fill of a covered part D drug to such individual will result in individual incurring costs that are equal to or above the annual out-of-pocket threshold specified in paragraph (4)(B) for such plan year, provide such individual with the option to make the coinsurance payment required under subparagraph (A) (for the portion of such costs that are not above such annual out-of-pocket threshold) in the form of periodic installments over the remainder of such plan year.";"